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1 ZUSAMMENFASSUNGDie Chronisch obstruktive pulmonäre Erkrankung (COPD) ist die vierthäufigste Todesursacheweltweit. Derzeit gibt es keine kurativen Therapieansätze und eine Lungentransplantation stelltdie einzige lebensverlängernde Behandlungsalternative dar. Allerdings führt der Mangel anSpenderorganen dazu, dass die Lungentransplantation nicht für alle Patienten angewendetwerden kann. Neue Therapieansätze werden daher dringend benötigt. In der vorliegenden Arbeitwurde eine Methode zur 3D ex vivo Kultivierung von Lungengewebe (3D-LTC) murinen undhumanen Ursprungs angewendet, um die Regeneration und Wiederherstellung vonLungengewebe in hoher örtlicher und zeitlicher Auflösung zu untersuchen.In einem ersten Schritt wurde die Herstellung und Kultivierung der 3D-LTC im Vergleich zubisherigen Methoden verbessert. Zell-Vitalität und –Proliferation konnten bis Tag sieben erhaltenwerden. Murine sowie humane Proben wurden mittels histologischer und Immunfluoreszenz-Färbungen, orts- und zeit-aufgelöster konfokaler live-cell-Mikroskopie als auch Gen- und Protein-Expressionsanalysen untersucht, um das Model der 3D-LTC hinsichtlich seiner Eignung zurUntersuchung von Signalwegsmodulationen zu charakterisieren. Wie bereits gezeigt, führte dieAktivierung des Wnt/beta-Catenin-Signalweges zur Verminderung des Elastase-induziertenEmphysem im Mausmodel [Kneidinger, et.al., 2011]. TGF-beta ist ein weitere Signalweg der eineRolle in der COPD spielt und ein TGF-beta-Mangel kann mit der Entwicklung des Emphysems inVerbindung gebracht werden [Budd, et.al., 2012]. Um weitere Erkenntnis über diemechanistischen Ursachen zu erhalten, wurden die COPD-relevanten Signalwege Wnt/beta-Catenin und TGF-beta in 3D-LTC von COPD Patienten und emphysematösen Mäusen aktiviert. Eskonnte gezeigt werden, dass die Aktivierung des Wnt/beta-Catenin Signalweges epithelialeReparaturmechanismen in den 3D-LTC induziert. Weiterhin korrelierten die Aktivierung desWnt/beta-Catenin-Signalweges sowie die Aktivierung von alveolären Typ-II-Epithelzellen mit demKrankheitsschweregrad des Patienten. Diese Ergebnisse weisen darauf hin, dass 3D-LTC vonPatienten für die Medikamentenevaluierung hinsichtlich personalisierter Medizin nützlich seinkönnen. Des weiteren war eine Aktivierung des TGF-beta-Signalweges in 3D-LTC möglich. TGF-beta führte zur Herstellung von Komponenten der extra-zellulären Matrix sowie der Expressionvon Transkriptionsfaktoren und Genen, die auf eine epitheliale-zu-mesenchymale Transitionhinweisen. Es kann daher geschlussfolgert werden, dass das in dieser Arbeit etablierte Model der3D-LTC die Quantifizierung sowie ort- und zeit-aufgelöste Visualisierung sowohl regenerativer alsauch remodulierender Prozesse in der Lunge möglich macht. Die individuelle Reaktion auf einebestimmte medikamentöse Behandlung kann damit besser prognostiziert werden. Dadurch stelltdas in dieser Arbeit etablierte Model der 3D-LTC ein ausgezeichnetes System zur pre-klinischenMedikamententestung dar.
2 | SUMMARY
2 SUMMARYChronic obstructive pulmonary disease (COPD) is the fourth leading cause of death worldwide. Atthe moment no curative treatment is available. Thus far, lung transplantation is the only optionhowever donor organ shortage limits its general clinical application. New therapies aredesperately needed. Here, 3D ex vivo lung tissue cultures (3D-LTC) from diseased murine andhuman lungs were applied to study repair and remodelling in high spatio-temporal resolution. Ina first step, the method of 3D-LTC generation and cultivation was optimized and improved. Cellviability and proliferation was maintained until day seven. Murine and human lung samples wereexamined by histology, immunofluorescence, spatio-temporal confocal live-cell-imaging, as well asgene and protein expression analyses to fully characterize the suitability of the model for signalpathway modulation. Previous reports demonstrated that Wnt/beta-catenin signal activation ledto attenuation of experimental emphysema in mice [Kneidinger, et.al., 2011]. TGF-beta is anotherpathway involved in COPD and a lack of TGF-beta seems to be related to the emphysematouschanges [Budd, et.al., 2012]. To get insight into disease underlying mechanisms the COPD-relevantsignalling pathways Wnt/beta-catenin and TGF-beta were activated in 3D-LTC from COPD patientsand emphysematous animals. It was demonstrated that Wnt/beta-catenin signal activationinitiated epithelial repair in 3D-LTC. Moreover, Wnt/beta-catenin pathway activation and alveolarepithelial type II cell activation significantly correlated with individual disease stage suggestingthat 3D-LTC from patients are suitable for individual drug validation and therapy prediction. TGF-beta signalling activation led to the production of extracellular matrix components and inducedexpression of transcription factors and genes involved in epithelial-to-mesenchymal transition. Inconclusion, the model of 3D-LTC established in this thesis allows quantification and spatio-temporal visualization of regenerative processes in the lung. It is suitable to validate and givefurther mechanistical insight of Wnt/beta-catenin and TGF-beta induced lung repair andremodelling, as well as treatment response prediction to individualized therapy. Thus, the 3D-LTCmodel presents a superior system for preclinical drug validation.
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3 INTRODUCTION
3.1 Lung repair and remodellingChronic lung diseases are second leading cause of death worldwide with very limited treatmentoptions. In most diseases such as chronic obstructive pulmonary disease (COPD) and idiopathicpulmonary fibrosis (IPF) no curative treatments are available and even keeping the “status quo” isnot possible. Clinicians are seeking new treatment options. Understanding disease onset,development, and progression together with the discovery of markers for early diagnosis is crucial.Several factors are involved in lung repair. A complex interaction of cells, matrix, and theappropriate activation status of various signalling pathways, is required for normal tissueregeneration. Three main components involved in endogenous lung repair are: 1) the endogenous(progenitor) cells (e.g. basal, broncho-alveolar duct junction, Clara, distal progenitor, and ATIIcells), 2) signalling pathways (e.g. wingless/integrase-1 (Wnt), sonic hedgehog (Shh),transforming growth factor (TGF) -beta, and Notch), and 3) the extracellular matrix (ECM) (withvarying composition and mechanical properties throughout the lung) [Rock, et.al., 2012]. It hasbeen shown that the lung, although known to be an organ of low tissue turnover (with less than1% of epithelial cells undergoing proliferation in 24 h [Crosby, et.al., 2010]), has the capability ofendogenous repair. For example, a cancer patient who had undergone lung resection at age 33 hadpronounced compensatory lung growth within 15 years [Butler, et.al., 2012].
3.1.1 Chronic obstructive pulmonary diseaseThe main focus of this thesis was to study lung repair in the chronic lung disease COPD, which isthe fourth leading cause of death worldwide (5% of all deaths globally in 2005) and will mostprobably increase in prevalence until 2030 [Churg, et.al., 2007, Stockley, et.al., 2009, WHO, Datelast updated: October 2013. Date last accessed: June 02 2014]. The main risk factor to developCOPD is tobacco smoke (direct smoking as well as second-hand smoke), while other environmentalpollutants and recurring infections of the lower respiratory tract during childhood are also knownto be involved in triggering the disease. Patients are most commonly classified using the GlobalInitiative for Chronic Obstructive Lung Disease (GOLD) stage (I-IV), which is based on lung functiondata from spirometer measurements [Rabe, et.al., 2007]. The forced expiratory volume in onesecond (FEV1) and its ratio to the forced vital capacity (FVC) is a measure for disease severity, isinfluenced by age, sex, height, and ethnicity, and expressed as percentage of predicted. COPD ismostly diagnosed in patients older than 40 years presenting with shortness of breath andproductive cough [Molfino, et.al., 2007, Rabe, et.al., 2007, Vestbo, et.al., 2013]. While there iscurrently no curative treatment, disease progression can only be decelerated by pharmacologicalintervention [Barnes, 2010, WHO, Date last updated: October 2013. Date last accessed: June 022014]. Mainly bronchodilators, corticosteroids, phosphodiesterase-4 inhibitors, and combinationsthereof are used for therapeutic intervention. While corticosteroids improve quality of life and
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reduce exacerbations, there is no uniform decline in lung function but is restricted to a small groupof patients [Barnes, 2010, Burge, 2001, Celli, et.al., 2008, Yang, et.al., 2007]. Patients with moderateto severe COPD suffer from progressive decline in lung function, necessitating long-termadministration of oxygen (>15 h/d), especially in patients with very severe COPD (stage IV). Theonly remaining option is lung transplantation, but due to the lack of donor organs, this is onlyavailable for a subgroup of patients and further bears the risk of developing a chronic allograftdysfunction, called bronchiolitis obliterans syndrome (BOS). The limitation of therapeuticintervention underlines the need for a better understanding of the disease to develop newtherapies.
3.1.2 Pathogenesis of COPDSmoke, as well as other environmental pollutants, repetitively injures lung epithelial cells, whichare lining the airways and alveoli, leading to infiltration of inflammatory cells into the airspaces.This inflammation is not pathogenic in non-susceptible smokers [Hogg, et.al., 2009, Sharafkhaneh,et.al., 2008]. In the subset of patients which are susceptible to develop COPD, pathogenicinflammation is enhanced and leads to chronic bronchitis, small airway obstruction, andperipheral airspace enlargement with alveolar destruction –called emphysema [Chung, et.al.,2008, Hogg, et.al., 2009, Sharafkhaneh, et.al., 2008]. Inflammation is not a singular cause for COPDprogression. New paradigms in COPD progression include alveolar epithelial cell senescence andpremature aging due to abnormalities in telomere length and expression of senescence-relatedcell-cycle regulators [Chilosi, et.al., 2012, Shi, et.al., 2012]. Furthermore, “second/additional hits”such as oxidative stress (caused by environmental exposure, such as cigarette smoke),protease/anti-protease imbalances, abnormal healing after injury, aberrant remodelling, andenhanced apoptosis, in addition to the missing ability of the lung to regenerate the injured tissue,are further causes for disease progression [Beasley, 2010, Sharafkhaneh, et.al., 2008].Small airway obstruction (also known as small airway disease), one of the main features of COPD,occurs due to airway narrowing affecting mainly airways smaller than 2 mm in diameter.Narrowing of the airways primarily occurs due to inflammation and peribronchial fibroticprocesses increasing small airway walls thickness [Hogg, et.al., 2004, McDonough, et.al., 2011,Sturton, et.al., 2008]. Airway epithelial cells and the smooth muscle cell layer are the main sitesaffected. Small airway disease furthermore contributes to progressive airflow limitation and airtrapping [Chung, 2005, Stockley, et.al., 2009]. The second main feature of COPD –emphysema– ischaracterised by airspace enlargement, loss of alveolar structure, and impaired alveolar repairprocesses. Emphysematous changes typically seen in the lung are shown in Figure 3.1.
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Figure 3.1: Emphysematous changes in patients with COPD showing airspace enlargement and alveolar
destruction.Haematoxylin-Eosin staining of 3D ex vivo lung tissue cultures (3D-LTC) from non-COPD and COPD patients. Insertsare showing a higher magnification. Scale bars 100 µm.An activation of macrophages contributes to the development of emphysema. Macrophages play acentral role in recruiting other inflammatory cells, such as neutrophils. Activated macrophages andneutrophils release proteases such as matrix metallo-proteinase (MMP), in particular MMP-9 andMMP-12 as well as neutrophil elastase (ela), leading to enhanced degradation of the alveolar ECM[Shapiro, 2002]. Moreover, activated macrophages and neutrophils secrete chemokines, whichfurther enhances recruitment and infiltration of the tissue by inflammatory cells (Figure 3.2). Thisvicious cycle is thought to be the driving force behind COPD progression [Sharafkhaneh, et.al.,2008].In addition, alveolar epithelial type (AT) I and II cells undergo apoptosis in response to cigarettesmoke, thereby worsening emphysema. ATI cells are the main cellular component of the alveoluscovering 95% of its surface area. The residual area is covered by ATII cells, which are known to beable to differentiate into ATI cells [Barkauskas, et.al., 2013, Rawlins, et.al., 2008]. ATI cells areelongated flat cells and are in close contact to the endothelial cells of the capillary networkseparated by a basement membrane only. Due to this, the barrier for gas exchange is no thickerthan 1-2 µm. This is important as gas exchange is driven by diffusion. Thickening this barrier leadsto tremendous reduction in oxygen uptake. Another important component for gas exchange issurfactant (from surface active agent), which is produced exclusively by ATII cells. Surfactantproteins help reducing the surface tension and thereby the resistance of the lung during breathing.By this, it is obvious that an abnormal reduction of ATI and/or ATII cells without fast and properrestoration is fatal.
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Figure 3.2: Scheme of airflow obstruction development caused by cigarette smoke.Cigarette smoke induces release of elastolytic enzymes by activated macrophages, neutrophils, and lymphocytesleading to emphysema. The airway epithelial cells release cytokines leading to airway remodelling and peribronchialfibrosis. In total, this leads to the airflow obstruction seen in COPD. Modified from [Sharafkhaneh, et.al., 2008].
3.2 Signalling pathways involved in lung repair
3.2.1 The wingless/integrase-1 (Wnt) signalling pathwayIn chronic lung diseases such as COPD and IPF, aberrant activation of Wnt signalling was shownby various groups [Chilosi, et.al., 2003, Ezzie, et.al., 2012, Kneidinger, et.al., 2011, Konigshoff, et.al.,2010, Konigshoff, et.al., 2009, Lam, et.al., 2011, Wang, et.al., 2011]. The Wnt signalling pathway ishighly conserved over species and is of importance in embryonic development as well as inpostnatal tissue repair and regeneration [Baarsma, et.al., 2013, Konigshoff, et.al., 2010]. Thepathway is divided into the canonical (beta-catenin-dependant) and the non-canonical (beta-catenin-independent) signalling axis. Wnt signalling components and modulators involve 19secreted Wnt ligands, 10 frizzled receptors (FZD), the low-density lipoprotein receptor relatedproteins (LRP) 5 and 6, and various extracellular modulators (e.g. Dickkopfs (DKK) 1-4). It hasbeen suggested that secreted Wnt ligands can compensate for each other, but Wnt1, 2, 3A, 8, and10B are known to induce canonical Wnt signalling, while Wnt5A and 11 predominantly mediatenon-canonical Wnt signalling [Al Alam, et.al., 2013, Baarsma, et.al., 2013, Niehrs, 2012].
3.2.1.1 Canonical Wnt signallingIn the absence of Wnt ligands, beta-catenin, the key effector of canonical Wnt signalling, is targetedby its destruction complex –consisting of axin, adenomatosis polyposis coli (APC), glycogen
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synthase kinase-3 (GSK3), casein kinase-1 (CK-1), and protein phosphatases (PP1, and PP2A). Thisleads to phosphorylation of beta-catenin, targeting it for proteasomal degradation, and keepingcytoplasmic levels low. When a secreted Wnt ligand is bound to its FZD receptor and co-receptorLRP5/6, the beta-catenin destruction complex is inactivated via phosphorylation of LRP5/6 byGSK3 and CK-1. By this, beta-catenin is no longer phosphorylated, no longer targeted forproteasomal degradation, can enrich in the cytoplasm, and translocate into the nucleus, leading toTCF/LEF-dependent gene transcription. Nuclear translocation seems to be FoxM1-dependent,which can bind to beta-catenin and contains a functional nuclear location signal [Zhang, et.al.,2011]. Target genes of canonical Wnt signalling vary depending on cellular and tissue context.Axin2, a negative feedback regulator, seems to be an exception by being context independent[Grigoryan, et.al., 2008, Nusse, 2012]. Functionally, the canonical Wnt pathway is mostpredominantly involved in cell proliferation and differentiation [Angers, et.al., 2009, Baarsma,et.al., 2013, Clevers, 2006, Konigshoff, et.al., 2010, Logan, et.al., 2004, Macdonald, et.al., 2007,MacDonald, et.al., 2009, Niehrs, 2012, Nusse, 2012].
3.2.1.2 Non-canonical Wnt signallingNon-canonical Wnt signalling can be divided into the planar cell polarity (PCP) pathway, the Wnt-Ca2+-pathway, and several other known pathways (e.g. Wnt-RAP-1, Wnt-ROR2, Wnt-PKA, Wnt-GSK3-MT, Wnt-aPKC, Wnt-RYK, and Wnt-mTOR), which are possibly overlapping with the PCP andWnt-Ca2+-pathway [Niehrs, 2012, Nusse, 2012, Semenov, et.al., 2007]. Following Wnt ligandbinding, the PCP pathway acts via the small GTPases Rho and Rac and does not require LRP5/6 fordownstream signalling. Thus, the PCP pathway is involved in cytoskeletal rearrangements,polarisation of cell sheets, and cell movements during gastrulation. The PCP and canonical Wntpathway can antagonize each other. Of particular note, Wnt5A, a ligand well-known for inducingnon-canonical Wnt signalling can inhibit Wnt3A-induced canonical Wnt signalling [Bryja, et.al.,2009, Niehrs, 2012].The Wnt-Ca2+-pathway acts via increasing intracellular Ca2+-levels which then leads to activationof phospholipase C (PKC), calmodulin-dependent protein kinase II (CAMKII), and nuclear factor ofactivated T-cells (NFAT), and, similar to the PCP pathway, can antagonize canonical Wnt signalling.The Wnt-Ca2+-pathway is known to be involved in development, cancer, inflammation, andneurodegeneration [Baarsma, et.al., 2013, De, 2011, Niehrs, 2012].
3.2.1.3 Wnt signalling in developmentThe Wnt signalling pathway is involved in development and tissue regeneration of different organsand therefore, tight regulation is crucial (see Grigoryan et al. for a comprehensive review)[Grigoryan, et.al., 2008]. Different signalling pathways, such as transforming growth factor (TGF)beta, sonic hedgehog (Shh), connective tissue growth factor (CTGF), and Notch, are known tointeract with Wnt signalling. For example, FGF and Shh pathways are major downstream targets
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of Wise-regulated Wnt signalling [Ahn, et.al., 2010]. The correct spatio-temporal signallingbetween the mesenchyme and epithelium is required for organogenesis [Hines, et.al., 2014]. Inparticular, Wnt signalling is known to be critical in lung development, regeneration and repair, andis deranged in a number of adult lung diseases such as pulmonary fibrosis, lung cancer, and COPD[Chilosi, et.al., 2012, Clevers, 2006, Konigshoff, et.al., 2010, Lam, et.al., 2011, Li, et.al., 2014, VanScoyk, et.al., 2008].The lung develops from the endoderm, specifically from the ventral foregut, a process where thecorrect allocation and expression of FGF9/10, bone morphogenic protein (BMP) 4, Wnt2/7B, andShh play key roles [Morrisey, et.al., 2010]. First, two buds are formed, which, eventually extendinto the left and right lung. This is followed by the pseudoglandular stage whereby “tree-like”branching occurs for several branching generations [Rawlins, 2008]. Wnt, BMP, and FGF play a keyrole in the pseudoglandular stage by transcriptional activation of Nkx2-1, the earliest marker ofthe pulmonary lineage.
3.2.1.4 Wnt signalling in disease and regenerationAberrant activation of canonical Wnt signalling can result in the development of cancers andcontributes to various fibroproliferative diseases [Clevers, 2006, Gosens, et.al., 2008, Konigshoff,et.al., 2008, Konigshoff, et.al., 2009, Lam, et.al., 2011]. Furthermore, decreased Wnt/beta-cateninsignalling has been demonstrated in human COPD samples and animal models of emphysema.Importantly, activation of Wnt/beta-catenin signalling by inactivation of GSK3 by LiCl led to anattenuation of experimental emphysema [Kneidinger, et.al., 2011, Zhou, et.al., 2012]. Wntsignalling is known to be involved in stem cell proliferation and renewal [Chilosi, et.al., 2012]. Inparticular, following epithelial injury, Wnt signalling is of major importance for epithelial repair.Mice lacking beta-catenin in alveolar epithelial cells showed increased alveolar epithelial cell deathand had more severe fibrosis in a bleomycin induced fibrosis model [Tanjore, et.al., 2013]. Further,knockdown of beta-catenin using a shRNA approach delayed epithelial repair [Zemans, et.al.,2011]. In contrast to other organs like the intestine, the respiratory epithelium has a very slowturnover rate, and it is evident that distortion of Wnt signalling has long-range effects on thefunctionality of the lung [Rock, et.al., 2011]. As discussed before, the entire process of regenerationand the reasons why some individuals develop lung disease due to improper repair while othersare protected is incompletely understood and needs further research to be able to develop newtreatments.
3.2.1.5 Pharmacological modulation of Wnt signallingWnt signalling is involved in the development and progression of various diseases such as cancer,neurologic diseases (e.g. Alzheimer), disorders of bone metabolism (e.g. osteoporosis),inflammatory diseases (e.g. fibrosis), etc. [Niehrs, 2012, Zimmerman, et.al., 2012]. In lung disease,canonical/non-canonical Wnt signalling is aberrantly activated. While it is reactivated in lung
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fibrosis, it was shown to be attenuated in COPD [Chilosi, et.al., 2012, Chilosi, et.al., 2003, Ezzie, et.al.,2012, Kneidinger, et.al., 2011, Konigshoff, et.al., 2008, Konigshoff, et.al., 2009, Lam, et.al., 2011,Wang, et.al., 2011]. Wnt signalling modulation is therefore an appealing treatment option forseveral chronic (lung) diseases. Various chemical compounds can be used to interfere with the Wntpathway [Baarsma, et.al., 2013, Kahn, 2014].Inhibition of Wnt signalling can be achieved by interfering with Wnt ligands (e.g. inhibitors of WNTproduction (IWPs) [Chen, et.al., 2009, Gopalsamy, et.al., 2008, Pelletier, et.al., 2009]), Wntsecretion (LGK974), FZD interaction with DVL [Fujii, et.al., 2007, Grandy, et.al., 2009, Shan, et.al.,2005]), the beta-catenin destruction complex (e.g. inhibitors of Wnt response (IWRs) [Gunaydin,et.al., 2012, Huang, et.al., 2009]), and interference with beta-catenin signalling (e.g. ICG-001 andIQ-1 [Emami, et.al., 2004]). Further examples for Wnt signalling antagonists are 1) Dickkopfproteins and Wise, which each act at the receptor level by binding to LRPs and blocking Wnt ligandbinding and 2) sFRPs and WIF-1, which directly bind to Wnt ligands and thereby interfere withreceptor binding.Wnt activation can be achieved by inactivation of the mentioned Wnt antagonists [Gopalsamy,et.al., 2008, Pelletier, et.al., 2009], inhibition of GSK3 (e.g. chiron inhibitor CT99021 (later calledCT), LiCl, SB216763, and SB415286 [Bain, et.al., 2007, Murray, et.al., 2004]), or a decrease of beta-catenin breakdown [Baarsma, et.al., 2013]. Most commonly, GSK3 inhibition is used. Bain andcolleagues recommended CT because it more specifically inhibits GSK3 as compared to other GSK3inhibitors [Bain, et.al., 2007]. Recently, LiCl was applied to attenuate emphysema in vivo[Kneidinger, et.al., 2011, Zhou, et.al., 2012]. A scheme of canonical Wnt signalling and the inhibitionof GSK3 for Wnt pathway modulation are depicted in Figure 3.3. The two pharmacologicalcompounds used in this study (LiCl and CT) are depicted as well.
Figure 3.3: Simplified scheme of canonical Wnt/beta-catenin signalling showing its main components.If no Wnt ligand is bound to its receptors (Frizzled and LRP 5/6) the destruction complex (consisting of APC, Axin, andGSK3) phosphorylates beta-catenin leading to its degradation by the proteasome. When a Wnt ligand is bound to its
10 | INTRODUCTION
receptors the destruction complex is attracted to the cell membrane and cannot phosphorylate beta-catenin anymoremaking it capable to trans-locate to the nucleus and induce TCF/LEF-dependent gene transcription. LiCl as well as CTinhibit the action of GSK3, thereby leading to pathway activation by prevention of beta-catenin phosphorylation anddegradation.
3.2.2 The TGF-beta signalling pathwayIn recent studies, a link between TGF-beta and beta-catenin signalling has been shown. Zhou andcolleagues confirmed the interaction of beta-catenin with phosphorylated SMAD3 (SMAD, the
Caenorhabditis elegans protein SMA (from the gene sma for small body size) and homolog of boththe Drosophila protein, mothers against decapentaplegic (MAD)) to form a ternary complexinducing alpha smooth muscle actin (alpha-SMA=Acta2) gene expression in rat lung epithelial cells[Zhou, et.al., 2012]. Furthermore, TGF-beta induced PI3K/Akt2-signalling, leading to inhibition ofGSK3 activity in renal tubular epithelial cells [Lan, et.al., 2014]. Additionally, it has been shown thatTGF-beta can induce active beta-catenin (ABC, a surrogate marker for active canonical Wntsignalling) via phosphorylation of GSK3 and upregulates beta-catenin mRNA levels [Baarsma, et.al.,2011, Baarsma, et.al., 2011]. This gives evidence, that TGF-beta and Wnt signalling are connectedto each other.The TGF-beta superfamily consists of activins, inhibins, BMP, and growth factors, e.g. TGF-beta1,TGF-beta2, and TGF-beta3 [Massague, 2008, Taylor, et.al., 2008]. TGF-beta is secreted by variouscell types and can be integrated into the extracellular matrix in a latent form and released again,by the action of proteases like thrombin, plasmin, and MMPs. Signalling is induced by binding ofligands to TGF-beta-receptor (TGFbR) I and II, which then form a heteromeric complex. Thiscoupling enables the kinase domain of the type II receptor to phosphorylate the type I receptor,leading to activation of small phenotype and mothers against decapentaplegic related proteinsignalling. There are different classes of SMAD proteins depending on their function, receptor-regulated (R-SMAD: SMAD1, SMAD2, SMAD3, SMAD5, SMAD8/9), common –mediator SMAD (co-SMAD: SMAD4), and antagonistic or inhibitory SMAD (I-SMAD: SMAD6, SMAD7). R-SMADs 2 and 3bind to the type I receptor, become phosphorylated, and then dissociate from the receptor again.Subsequently, a complex of phosphorylated SMAD2/3 is formed with SMAD4 and this complexinteracts with a broad range of DNA-binding partners in the nucleus to regulate gene expression.A simplified scheme of canonical TGF-beta signalling showing its main components is depicted inFigure 3.4. One target gene of canonical smad signalling is SMAD7, which has an inhibitory effecton SMAD2/3 signalling. The SMAD7 protein can act as a negative feedback regulator byrecruitment of E3 ubiquitin ligases and smad ubiquitin regulatory factors 1/2 (smurf1/2) tomediate receptor turnover, thereby inhibiting TGF-beta signalling [Taylor, et.al., 2008].Additionally, TGF-beta can induce SMAD-independent signalling leading to activation of severalother pathways (e.g. JNK, p38, p42/44 (ERK), and PI-3-kinase pathways) [Budd, et.al., 2012, Zhang,2009].
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Figure 3.4: Simplified scheme of canonical TGF-beta signalling showing its main components.When TGF-beta is bound to its receptors (TGFbR I, II) SMAD2 and 3 become phosphorylated, form a complex withSMAD4 and translocate to the nucleus leading to target gene expression. SMAD7 inhibits TGF-beta signalling.
3.2.2.1 TGF-beta and epithelial-to-mesenchymal transitionIt is well established, that TGF-beta induces epithelial-to-mesenchymal transition (EMT)[Santibanez, et.al., 2011, Willis, et.al., 2007]. EMT is a fundamental process involved in celldifferentiation during development and tumour invasion [Bartram, et.al., 2004, Morty, et.al., 2009,Nawshad, et.al., 2005, Thiery, et.al., 2006]. During EMT, epithelial cells differentiate intomesenchymal cells being critical for the development of mesoderm from the endoderm and fororgan development in general. This cellular differentiation is characterized by a loss of cellularjunctions, mainly E-cadherin and zona occludens-1 (ZO-1), accompanied by increase in alpha-SMA,collagen I, and the transcription factors Snai1 and Snai2 (also known as Snail and Slug) [Crosby,et.al., 2010, Grande, et.al., 2002, Kim, et.al., 2006, Milara, et.al., 2013, Tanjore, et.al., 2011, Thiery,et.al., 2006]. Other mesenchymal markers can be used to determine the progression of EMT as well,e.g. vimentin, connective tissue growth factor, N-cadherin, and MMPs [Willis, et.al., 2007],depending on the context in which EMT occurs. In a fibrotic setting, such as peribronchialremodelling seen in COPD, EMT is characterized by an increase in fibroblasts and myo-fibroblasts.However, not all mesenchymal markers are exclusively expressed by these cells. For this reason, acombination of different markers and readouts is necessary to analyse EMT.
3.2.2.2 TGF-beta in COPD and lung cancerIn COPD, the role of TGF-beta is controversial. On the one hand, peribronchial remodelling withfibrosis, being responsible for airway obstruction, is due to excessive fibrogenic growth factorrelease, especially TGF-beta [Beasley, 2010, Churg, et.al., 2006]. Furthermore, single nucleotidepolymorphisms in the TGF-beta gene are associated with COPD development and smokers as wellas COPD patients are reported to have an increased expression of TGF-beta [Chung, 2001, de Boer,et.al., 1998, Kneidinger, et.al., 2011, Takizawa, et.al., 2001, van Diemen, et.al., 2006]. TGF-beta can
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be activated in lung fibroblasts and various other pro-fibrotic factors can be secreted from theairways by cigarette smoke [Churg, et.al., 2006, Wang, et.al., 2003]. In addition, fibroblasts derivedfrom COPD patients produced more ECM proteins providing a pro-fibroproliferative environmentupon cigarette smoke exposure compared to control cells [Krimmer, et.al., 2012]. This is inaccordance to the finding, that TGF-beta expression is increased while the I-SMADs SMAD6 and 7are reduced in the airway epithelium of patients with COPD [de Boer, et.al., 1998, Santibanez, et.al.,2011]. On the other hand, the emphysematous changes seen in the alveolar regions seem to berelated to a lack of TGF-beta [Budd, et.al., 2012, Milara, et.al., 2013]. This shows that TGF-betaeffects are highly context and cell-type specific.Similarly, TGF-beta has differential consequences in the development of cancer, depending oncellular context and the microenvironment. In early stages TGF-beta has been shown to be tumour-suppressive and anti-proliferative, while in later stages TGF-beta becomes pro-oncogenic,inducing proliferation, angiogenesis, immunosuppression, invasion, and metastasis [Adcock, et.al.,2011, Derynck, et.al., 2001, Juarez, et.al., 2011, Massague, 2008, Santibanez, et.al., 2011]. Moreinsight into the role of TGF-beta signalling in cancer and COPD will help to develop therapeuticoptions for the patients.
3.3 Translational medicine and preclinical modelsAs already mentioned before, chronic lung diseases are the second leading cause of deathworldwide. Many patients die awaiting transplantation since donated organs cannot cover theneed. Several approaches have addressed the question how to overcome this shortage: Donororgans are preserved and perfusion pre-treated to make “non-optimal” lungs suitable fortransplantation [Bruinsma, et.al., 2014, Butler, et.al., 2002, Cypel, et.al., 2011, op den Dries, et.al.,2013]. Furthermore, the approach of engineering organs ex vivo has gained broad scientificinterest. For this, donor lungs are decellularized and recellularized with patient specific cells toavoid the need for immunosuppression. Initial studies done in animals are promising but organsare only functional for short periods (hours to days) [Gilpin, et.al., 2014, Ott, et.al., 2010, Petersen,et.al., 2010]. More work needs to be done and will take most probably additional 10-20 years untilwhole engineered organs will be clinical applicable.Due to this, new treatment options to treat chronic lung diseases are needed and new models andtest systems need to be developed. The problem of translating results from animal models into theclinics are due to small sample size, age and gender differences, different onset and diseaseprogression, and missing of comorbidities in mice compared to humans [Herter-Sprie, et.al., 2013].Moreover, personalized approaches are needed since patient heterogeneity prevents the usage ofa universal applicable treatment. Some progress has already been made in this regard. In cancerresearch, a new model of “mouse avatars” is used to get insight into disease development andprogression to predict individual-specific chemotherapy treatment outcomes [Malaney, et.al.,2014]. Patient derived tumour samples are implanted into mice, which then undergo drug efficacystudies. Dekkers and colleagues described an assay for personalized medicine, using long-term
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cultivation of primary intestinal organoids derived from patients with cystic fibrosis, robustlydiscriminating healthy and diseased patients [Dekkers, et.al., 2013]. With this assay, they proposeto facilitate diagnosis and drug development for cystic fibrosis. Moll and colleagues developed amethod to model cancer tumours in a 3D environment combining primary human dermalfibroblasts, primary human microvascular endothelial cells, and a tumour cell line in 2D and 3Dculture in a decellularized porcine jejunal segment [Moll, et.al., 2013]. This model could possiblybe used to analyse pharmaceuticals for clinical application.All of these approaches use isolated cells or tissue samples to study pharmacological interventionpossibly not representing the whole complexity of the tissue present in the patient. The approachof culturing patient tissue ex vivo is suggested to be more appropriately mimicking the in vivosituation. This can be achieved by cultivation of isolated patient tissues (for example from biopsiesor resections). One such method that was already described in the late 1980s is the method ofprecision cut tissue (e.g. lung) cultures.
3.4 Precision cut tissue slices – 3D ex vivo lung tissue culturesThe name “precision cut tissue slices” was established in the mid-eighties, when Smith et al. firstreported a method to slice liver into 250 µm thin sections with low variation in thickness (<5%)for cultivation and analysis ex vivo [Smith, et.al., 1985]. Previously, slices (predominately fromliver) were produced by hand with high variability in thickness (one to several mm) and the riskof malnutrition and oxygenation of cells in the middle of slices from high cell density organs limitedthis approach [Sanderson, 2011]. The development of the Krumdieck tissue slicer helpedovercome many of these issues by allowing for precise cutting of slices of less than one mmthickness (in general 25-300 µm) [Liberati, et.al., 2010, Sanderson, 2011].This ex vivo slicing method has been applied to several organs, such as brain [Pilaz, et.al., 2014,Wang, et.al., 2014], heart [Bussek, et.al., 2009, Camelliti, et.al., 2011, Parrish, et.al., 1995], liver [deGraaf, et.al., 2010, De Kanter, et.al., 1999, Hammad, et.al., 2014, Parrish, et.al., 1995, Satoh, et.al.,2005], kidney [De Kanter, et.al., 1999, Parrish, et.al., 1995, Rice, et.al., 2013], organ of Corti [Shim,2011], and lung [Davidovich, et.al., 2013, De Kanter, et.al., 1999, Delmotte, et.al., 2006, Liberati,et.al., 2010, Martin, et.al., 1996, Morin, et.al., 2013, Parrish, et.al., 1995].Furthermore, this technique was applied to organs from various species including mice [Delmotte,et.al., 2006, Henjakovic, et.al., 2008, Schleputz, et.al., 2012, Schnorbusch, et.al., 2012], rats[Davidovich, et.al., 2012, de Graaf, et.al., 2010, Martin, et.al., 1996, Moreno, et.al., 2006, Nguyen,et.al., 2013, Schleputz, et.al., 2012], guinea pigs [Bussek, et.al., 2009, Ressmeyer, et.al., 2006,Schleputz, et.al., 2012], sheep [Schleputz, et.al., 2012], dogs [Nguyen, et.al., 2013], ferrets [Nguyen,et.al., 2013], monkeys [Nguyen, et.al., 2013, Schleputz, et.al., 2012], and humans [Camelliti, et.al.,2011, de Graaf, et.al., 2010, De Kanter, et.al., 1999, Schleputz, et.al., 2012, Wohlsen, et.al., 2003].For the generation of the slices, the lung is perfused with low-melting agarose as a support-material, providing the necessary stiffness. When the tissue slices are placed in culture, the agaroseis washed out and an intact 3D lung tissue remains.
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Studies using such lung tissue slices have been diverse, including pulmonary physiology,pharmacology, pathogenesis, toxicity, stretch, cytokine release, and viral exacerbations. [Bauer,et.al., 2010, Dassow, et.al., 2010, Davidovich, et.al., 2013, Davidovich, et.al., 2012, Held, et.al., 1999,Henjakovic, et.al., 2008, Liberati, et.al., 2010, Morin, et.al., 2013, Parrish, et.al., 1995, Rausch, et.al.,2011, Schleputz, et.al., 2010, Wright, et.al., 2008, Wyatt, et.al., 2012, Zhou, et.al., 2012]. Typicalexperimental durations have been reported in the range of 24-72 h, but there has been noextensive characterisation of the cultivation conditions. Most studies use videomicroscopy toanalyse the constricting or dilating effect of pharmacological compounds on the bronchi and/orsmall vessels. Only one pathway modulation study has been performed up to date focusing oncancer samples in general and targeting the PI3K/Akt signalling pathway, which plays a prominentrole in cancer [Vaira, et.al., 2010]. This thesis is the first study combining modulation of signallingpathways involved in chronic lung disease (here: Wnt and TGF-beta) with 3D ex vivo tissuecultivation.Even though animal models to study human lung diseases improve, there is still a major lack intranslating these results into the clinics. Many pre-clinical and clinical phase studies are still failing.This indicates that there is an urgent need to develop better models or approaches that can beapplied in a personalized medicine manner.
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3.5 Hypothesis and aims of this thesisWe hypothesised that murine and patient-derived 3D ex vivo lung tissue cultures (3D-LTC)represent a suitable tool for signal pathway modulation and preclinical drug testing in COPD.The first aim of the thesis was to establish the 3D-LTC model as a tool to study lung repair in miceand extensively/comprehensively validate an improved protocol with longer cultivation periods.Further, the 3D-LTC model should be adapted to human tissue biosamples from COPD patients.Comprehensive characterisation of mouse and human lung samples should comprise metabolicand proliferation assessment, morphological examination by histology, immunofluorescence,spatio-temporal confocal live-cell-imaging, as well as gene and protein expression analyses.The second aim of the thesis was to modulate specific signalling pathways in the 3D-LTC in orderto provide proof of concept evidence for the suitability of this technology to study disease-underlying mechanisms and validate novel drugs. In particular, we aimed to investigate theunderlying mechanisms of the observed attenuation of emphysema formation upon activation ofWnt/beta-catenin signalling [Kneidinger, et.al., 2011]. This should be achieved by Wnt/beta-catenin activation with two well-known compounds LiCl and CT, respectively. Moreover, we aimedto analyse lung remodelling by the induction of TGF-beta, a well known growth factor activated inlung disease, including COPD.
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4 MATERIALS	AND	METHODS
4.1 Materials
4.1.1 Laboratory equipment and software
Table 4.1: Laboratory equipment
Product Manufacturer-80 °C freezer U570 HEF New Brunswick; Hamburg, Germany-20 °C freezer MediLine LGex 410 Liebherr; Biberach, GermanyAgarose gel running chamber Biorad; Hercules, CA, USAAnalytical scale XS20S Dual Range Mettler Toledo; Gießen, GermanyAutoclave DX-45 Systec; Wettenberg, GermanyAutoclave VX-120 Systec; Wettenberg, GermanyBioanalyzer 2100 Agilent; Böblingen, GermanyCell culture work bench Herasafe KS180 Thermo Fisher Scientific; Darmstadt, GermanyCentrifuge MiniSpin plus Eppendorf; Hamburg, GermanyCentrifuge Rotina 420R Hettich; Tuttlingen, GermanyCentrifuge with cooling, Micro200R Hettich; Tuttlingen, GermanyCO2 cell Incubator BBD6620 Thermo Fisher Scientific; Darmstadt, GermanyDemineralized water Thermo Fisher Scientific; Darmstadt, GermanyDish washer G7893 Miele & Cie. KG; Gütersloh, GermanyDispenser, Ceramus 2-10ml Hirschmann Laborgeräte; Eberstadt, GermanyDry ice container Forma 8600 Series, 8701 Thermo Fisher Scientific; Darmstadt, GermanyElectronic pipet filler Eppendorf; Hamburg, GermanyElectrophoretic Transfer Cell, Mini Protean Tetra Cell Biorad; Hercules, CA, USAFilm developer Curix 60 AGFA; Morsel, BelgiumFridge MediLine LKv 3912 Liebherr; Biberach, GermanyGel electrophoresis chamber MINIeasy Carl Roth; Karlsruhe, GermanyGel imaging system ChemiDoc XRS+ Biorad; Hercules, CA, USAHyrax M55 (microtome) Zeiss; Jena, GermanyIce machine ZBE 110-35 Ziegra; Hannover, GermanyIntelli-Mixer RM-2 Schubert & Weiss Omnilab; Munich, GermanyLight Cycler LC480II Roche Diagnostics; Mannheim, GermanyLiquid nitrogen cell tank BioSafe 420SC Cryotherm; Kirchen/Sieg, GermanyLiquid nitrogen tank Apollo 200 Cryotherm; Kirchen/Sieg, GermanyMagnetic stirrer KMO 2 basic IKA; Staufen, GermanyMastercycler gradient Eppendorf; Hamburg, GermanyMastercycler Nexus Eppendorf; Hamburg, Germany
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Micro-Dismembrator S Thermo Fisher Scientific; Darmstadt, GermanyMicrom EC 350-1 Thermo Fisher Scientific; Darmstadt, GermanyMicrom EC 350-2 Thermo Fisher Scientific; Darmstadt, GermanyMicrom STP 420D Thermo Fisher Scientific; Darmstadt, GermanyMicroscope Axio Imager M2 (flourescence) Zeiss; Jena, GermanyMicroscope Axiovert 40 Zeiss; Jena, GermanyMicroscope LSM 710 (confocal) Zeiss; Jena, GermanyMirax Scan (slide scanner) Zeiss; Jena, GermanyMultipette stream Eppendorf; Hamburg, GermanyNanoDrop 1000 PeqLab; Erlangen, GermanypH meter InoLab pH 720 WTW; Weilheim, GermanyPipettes Research Plus Eppendorf; Hamburg, GermanyPlate centrifuge 5430 Eppendorf; Hamburg, GermanyPlate reader Sunrise Tecan; Crailsheim, GermanyRoll mixer VWR International; Darmstadt, GermanyPower Supply Power Pac HC Power Supply Biorad; Hercules, CA, USAScale XS400 2S Mettler Toledo; Gießen, GermanyShaker Duomax 1030 Heidolph; Schwabach, GermanySyringe pump "aladdin" AL-1000 World Precision instruments; Sarasosta, FL, USAThermomixer compact Eppendorf; Hamburg, GermanyUltra pure water supply MilliQ Advantage A10 Merck, Millipore; Darmstadt, GermanyLSM Top table centrifuge MCF-2360 Schubert & Weiss Omnilab; Munich, GermanyVortex Mixer IKA; Staufen, GermanyVacuum pump NO22AN.18 with switch 2410 KNF; Freiburg, GermanyVibratome Hyrax V50 Zeiss; Jena, GermanyWater bath Aqua Line AL 12 Lauda; Lauda-Königshofen, Germany
Table 4.2: Software
Software ProducerAxio Vision LE (AxioVs40 V 8.4.2.0) Zeiss; Jena, GermanyEndnote X7.0.2 Thomson Reuters; San Francisco, CA, USAGraphPad Prism 5.00 GraphPad Software; La Jolla, CA, USAIMARISx64 (version 7.6.4) Bitplane; Zurich, SwitzerlandImage Lab Version 5.0 Biorad; Hercules, CA, USALightCycler® 480 SW 1.5 Roche Diagnostics; Mannheim, GermanyMagelan Software Tecan; Crailsheim, GermanyMicrosoft Office Professional Plus 2010 Microsoft Corporation; Washington, DC, USAPannoramic Viewer 1.15.2 3DHistech Kft; Budapest, HungaryTristar MicroWin 2000 Berthold Technologies; Bad Wildbach, GermanyZen 2010 Zeiss; Jena, Germany
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4.1.2 Chemicals and consumables
Table 4.3: Chemicals and reagents
Product Manufacturer5-bromo-4-chloro-3-indolyl-β-d-galactopyranoside(X-Gal) Research Product International; Mount Prospect,IL, U.S.A10x Buffer II Applied Biosystemes, Life Technologies;Carlsbad, CA, USA87% Glycerol AppliChem; Darmstadt, GermanyAcetic acid Merck, Millipore; Darmstadt, GermanyAceton AppliChem; Darmstadt, GermanyAgarose Biozym Biozym Scientific GmbH; Oldendorf, GermanyAgarose, low melting point Sigma-Aldrich; Taufkirchen, GermanyAmmonium peroxodisulfate (APS) AppliChem; Darmstadt, GermanyAmphotericin B solution (250 µg/ml) Sigma-Aldrich; Taufkirchen, GermanyBiopsy punsh (4 mm, 6 mm diameter) pfm medical; Köln, GermanyBovine serum albumin (BSA) Sigma-Aldrich; Taufkirchen, GermanyBromphenol blue AppliChem; Darmstadt, GermanyCell Proliferation Reagent WST-1 Roche Diagnostics; Mannheim, GermanyComplete® Mini without EDTA (Protease-inhibitor) Roche Diagnostics; Mannheim, GermanyCoomassie Brilliant Blue R-250 staining solution BioRad; Hercules, CA, USACT Tocris/R&D; Minneapolis, MN, USADAPI (4',6-diamidino-2-phenylindole) Sigma-Aldrich; Taufkirchen, GermanyDesoxyribonucleotides mix (dNTPs) Fermentas; Thermo Fisher Scientific;Dimethyl formamide Serva; Heidelberg, GermanyDimethyl sulfoxide (DMSO) Carl Roth; Karlsruhe, GermanyDithiothreitol (DTT) AppliChem; Darmstadt, GermanyD-MEM/F12 Gibco, Life Technologies; Carlsbad, CA, USADNase/RNAse – free water Gibco, Life Technologies; Carlsbad, CA, USAEosin Y (yellowish) Merck, Millipore; Darmstadt, GermanyEthanol (p.a.) AppliChem; Darmstadt, GermanyFentanyl Janssen-Cilag; Neuss, GermanyFetal bovine serum (FBS) "GOLD", heat inactivated PAA/GE Healthcare; Fairfield, CT, USAFluorescence mounting medium Dako; Hamburg, DeutschlandFuchsin acid Merck, Millipore; Darmstadt, GermanyGelatin Sigma-Aldrich; Taufkirchen, GermanyGlucose AppliChem; Darmstadt, GermanyGlycine, molecular biology grade AppliChem; Darmstadt, GermanyGoTaq G2 Hot Start Green Master Mix, 2x Promega; Mannheim, GermanyHematoxylin (cryst.) Merck, Millipore; Darmstadt, GermanyHEPES Life Technologies; Carlsbad, CA, USA
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HI-MO Fast drying mounting medium forcoverslipping Bio-Optica; Milan, ItalyHydrochloric acid AppliChem; Darmstadt, GermanyIron(III) chloride hexahydrate Merck, Millipore; Darmstadt, GermanyIsopropanol, p.a. AppliChem; Darmstadt, GermanyKetamine Bela-pharm, Vechta, GermanyLiCl Sigma-Aldrich; Taufkirchen, GermanyLight Cycler 480 SybrGreen l Master Mix Roche Diagnostics; Mannheim, GermanyLight green SF yellowish Merck, Millipore; Darmstadt, GermanyMagnesium chloride AppliChem; Darmstadt, GermanyMagnesium chloride hexahydrate AppliChem; Darmstadt, GermanyMedetomidine Orion Pharma; Hamburg, GermanyMethanol, p.a. AppliChem; Darmstadt, GermanyMidazolam Roche Diagnostics; Mannheim, GermanyMolybdatophosphoric acid hydrate Merck, Millipore; Darmstadt, GermanyNon-fat dried milk powder AppliChem; Darmstadt, GermanyNonidet P-40 AppliChem; Darmstadt, GermanyOrange G Merck, Millipore; Darmstadt, GermanyOxalic acid dihydrate Merck, Millipore; Darmstadt, GermanyParaffin Richard Allen Scinetific; Kalamazoo, MI, USAPenicillin-Streptomycin (10,000 U/ml) Gibco, Life Technologies; Carlsbad, CA, USAPhosphate buffered saline Gibco, Life Technologies; Carlsbad, CA, USAPhosSTOP Phosphatase Inhibitor Cocktail Tablets Roche Diagnostics; Mannheim, GermanyPonceau S solution Sigma-Aldrich; Taufkirchen, GermanyPotassium ferricyanide Sigma-Aldrich; Taufkirchen, GermanyPotassium ferrocyanide Sigma-Aldrich; Taufkirchen, GermanyPotassium permanganate Merck, Millipore; Darmstadt, GermanyRandom hexamers Applied Biosystemes, Life Technologies;Carlsbad, CA, USARecombinant human TGF-β1protein R&D Systems; Minneapolis, MN, USAResorcin-fuchsin Carl Roth; Darmstadt, GermanyRestore Plus Western Blot Stripping Buffer Pierce, Thermo Fisher Scientific; Schwerte,GermanyRotiphorese Gel 30 (37,5:1) 500 ml Carl Roth; Darmstadt, GermanySodium dodecyl sulphate (SDS) pellets Carl Roth; Darmstadt, GermanySodium chloride AppliChem; Darmstadt, GermanySodium chloride, isotonic (for injection) B. Braun; Melsungen, GermanySodium hydroxide AppliChem; Darmstadt, GermanySodium phosphate monobasic Sigma-Aldrich; Taufkirchen, GermanySodium phosphate dibasic Sigma-Aldrich; Taufkirchen, GermanySuperSignal West Dura Extended DurationSubstrate Pierce, Thermo Fisher Scientific; Schwerte,GermanySuperSignal West Femto Substrate Pierce, Thermo Fisher Scientific; SchwerteGermany
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SybrSafe (10,000x in DMSO) Invitrogen Life Technologies; Carlsbad, CA, USATratrazine Sigma-Aldrich; Taufkirchen, GermanyTEMED AppliChem; Darmstadt, GermanyT-PER Tissue Protein Extraction Reagent Pierce, Thermo Fisher Scientific; Schwerte,GermanyTris base, buffer grade AppliChem; Darmstadt, GermanyTriton X-100 AppliChem; Darmstadt, GermanyTween 20 AppliChem; Darmstadt, GermanyUltraPure DNase/RNase-Free Distilled Water Invitrogen, Life Technologies; Carlsbad, CA, USAWST-1 Roche Diagnostics; Mannheim, GermanyXylene AppliChem; Darmstadt, GermanyXylazinhydrochloride cp-pharma; Burgdorf, Germany
Table 4.4: Consumables
Product Manufacturer96 Well, Black/Clear, Tissue Culture TreatedPlate, Flat Bottom with Lid BD Bioscience, Heidelberg, GermanyCannulas (G20, G21, G26) B. Braun; Melsungen, GermanyCell culture dishes Corning, Thermo Fisher Scientific; Schwerte,GermanyCell culture multi well plates TPP Techno Plastic Products; Trasadingen,SwitzerlandCryovials for microdismembrator 1.2 ml Nalgene, Thermo Fisher Scientific; SchwerteFalcon tubes (15 ml, 50 ml) BD Bioscience, Heidelberg, GermanyFilter tips Biozym Scientific; Hessisch Oldendorf,GermanyGlas Pasteur pipettes VWR International; Darmstadt, GermanyGrinding balls (9 mm, stainless steel) Neolab; Heidelberg, GermanyHyperfilm® ECL™ Film Amersham, GE Healthcare; Freiburg, GermanyMeasuring pipettes sterile, single use (2 ml,5 ml, 10 ml, 25 ml, 50 ml) VWR International; Darmstadt, GermanyNitrocellulose membrane Biozym Scientific; Hessisch Oldendorf,GermanyPCR plates Kisker Biotech; Steinfurt, GermanyReaction tubes (0.5 ml, 1.5 ml, 2 ml) Eppendorf; Hamburg, GermanyGreiner Bio-One; Frickenhausen, GermanyScalpel B. Braun; Melsungen, GermanySealing foil for PCR plates Kisker Biotech; Steinfurt GermanySyringes (1 ml, 10 ml, 20 ml) B. Braun; Melsungen, GermanyHenke-Sass Wolf; Tuttlingen, GermanyTips Eppendorf; Hamburg, GermanyKisker Biotech; Steinfurt, GermanyWhatman blotting paper 3 mm GE Healthcare; Freiburg, Germany
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4.1.3 Buffers, solutions and media
Table 4.5: Buffers, solutions and media
Buffer/Solution Concentration/amount Substance
Cultivation medium 1%2.5 µg/ml0.1%
DMEM/F12PSAmphotericin BFBSHEPES(N-2-hydroxyethylpiperazine-N-2-ethane sulfonic acid) 1 M HEPES
Laemmli loading buffer (4x) 8% (w/v)40% (v/v)traces250 mM400 mM
SDSGlycerolBromophenol blueTris/HCl, pH 6.8DTT freshly added
LacZ-staining solution 5 mM5mM2mM65 mM15 mM
Potassium ferricyanidePotassium ferrocyanideMagnesium chloride hexahydrateSodium phosphate dibasicSodium phosphate monobasic
PBS pH 7.4 (10x) 1.37 M27 mM100 mM20 mM
NaClKClNa2HPO4KH2PO4
PBND-buffer (1x)
50 mM10 mM2.5 mM0.1 mg/ml0.45% v/v0.45% v/v0.2 mg/ml
KClTris·HCl pH 8,3MgCl2gelatinNP40Tween-20Proteinase K (20 mg/ml)
Phosphomolybdate solution 0.4 g/l0.2 g/l Molybdatophosphoric acidhydrateOrange G
Ponceau-fuchsin 0.67 g/l0.33 g/l2 mM Ponceau SFuchsin acidAcetic acid
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RIPA protein lysis buffer
150 mM10 mM0.1% (w/v)1% (v/v)1% (w/v)5 mM
NaClTris/HCl, pH 7.2SDSTriton X-100Sodium deoxy cholateEDTA
SDS-PAGE Running Buffer 250 mM1.92 M1% (w/v) Tris/HCl, pH 7.4GlycineSDS
TAE (50x) 2 M5.71% (v/v)50 mM Tris/HClGlacial acetic acidEDTA, pH 8
TBS, pH 7.4 (10x) 10 mM150 mM Tris/HCl pH 7.4NaCl
TBST TBS supplemented with 0.05%Tween-20
Transfer Buffer (10x) 50 mM400 mM Tris/HClGlycine
Transfer Buffer (1x) 10%200 ml 10x Transfer BufferMethanol
Weigerts-staining solution 50%50% Weigerts-solution component AWeigerts-solution component BWeigerts-solution component A 5 g/l in 96% ethanol Heamatoxylin
Weigerts-solution component B 11.6 g/l1.5 M Iron(III) chloride hexahydrateHCl
X-Gal solution (light protected) 40 mg/mlin DMF 5-bromo-4-chloro-3-indolyl-β-d-galactopyranoside (X-Gal)X-Gal/LacZ solution (lightprotected) 250 µl9.75 ml X-Gal solutionLacZ-staining solution
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4.1.4 Standards and Kits
Table 4.6: Standards
Product Manufacturer100 bp DNA ladder Peqlab; Erlangen, GermanyProtein marker V Peqlab; Erlangen, GermanyQuick StartTM Bovine Serum Albumin (BSA)Standard Biorad; Hercules, CA, USA
Table 4.7: Kits
Product ManufacturerAgilent RNA 6000 Nano Kit Agilent; Böblingen, GermanyBCA Protein Assay Kit Pierce, Thermo Fisher Scientific; Schwerte,GermanyCell Proliferation ELISA, BrdU (colorimetric) Roche Diagnostics; Mannheim, GermanyLIVE/DEAD® Viability/Cytotoxicity Kit *formammalian cells* Invitrogen Life Technologies; Carlsbad, CA,USAPerfectPure RNA Fibrous Tissue Kit 5Prime; Hilden, GermanyRNeasy Mini Kit Qiagen; Hilden, GermanySFTPC ELISA (mouse and human) Cusabio; Wuhan, China
4.1.5 Enzymes
Table 4.8: Enzymes
Product ManufacturerPorcine pancreatic elastase Sigma-Aldrich; Taufkirchen, GermanyProteinase K Pierce, Thermo Fisher Scientific; Schwerte, GermanyRNase inhibitor 20 U/µl Applied Biosystems, Invitrogen, Life Technologies;Carlsbad, USAMuLV Reverse Transcriptase 5,000 U Applied Biosystems, Invitrogen, Life Technologies;Carlsbad, USA
4.1.6 OligonucleotidesOligonucleotides were purchased from Eurofins MWG Operon; Ebersberg, Germany in alyophilized, desalted form and reconstituted with DNase/RNase–free water to obtain aconcentration of 100 µM. Primers for qPCR were designed with PrimerBLAST from NCBI(http://www.ncbi.nlm.nih.gov/tools/primer-blast/). Amplicon size was between 80 and 150 bpwith maximal length of 200 bp.
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Table 4.9: Primers for genotyping
Mouse Gene Jackson ID Sequence 5’ - 3’ Size[bp]BAT-GAL, TOP-GAL Transgene oIMR3054 fw ATCCTCTGCATGGTCAGGTC 315oIMR0040 rv CGTGGCCTGATTCATTCCInternalcontrol oIMR8744 fw CAAATGTTGCTTGTCTGGTG 210oIMR8745 rv GTCAGTCGAGTGCACAGTTT
TCF/LEF-EGFP Transgene 11775 fw ACAACAAGCGCTCGACCATCAC ~53011776 rv AGTCGATGCCCTTCAGCTCGATInternalcontrol oIMR7338 fw CTAGGCCACAGAATTGAAAGATCT 324oIMR7339 rv GTAGGTGGAAATTCTAGCATCATCC
Table 4.10: Murine quantitative PCR primers
Gene Sequence 5’ - 3’
Aqp5 fw CCTTATCCATTGGCTTGTCGrv CTGAACCGATTCATGACCAC
Axin1 fw CGAAGGGAGATGCAGGAGAGTArv AAGTGCGAGGAATGTGAGGTAGA
Axin2 fw AGCAGAGGGACAGGAACCArv CTGAACCGATTCATGACCAC
Dkk2 fw GAGATCGCAACCATGGTCACTrv GGGTCTCCTTCATGTCCTTTTATATG
Fgfr2 fw ACACAGATAGCTCCGAAGACGTTGTrv CCCAGCCGGACAGCGGAACT
Hopx fw TCTCCATCCTTAGTCAGACGCrv GGGTGCTTGTTGACCTTGTT
Hprt fw CCTAAGATGAGCGCAAGTTGAArv CCACAGGACTAGAACACCTGCTAA
Lef1 fw GGCGGCGTTGGACAGATrv CACCCGTGATGGGATAAACAG
Lgr5 fw GCGTTCACGGGCCTTCACAGrv GGCATCTAGGCGCAGGGATTGA
Nkd1 fw TGTTCTCATCCACGCAATGGrv GAGCCCCACTCAGGTTCCA
Pdpn fw ACAGGTGCTACTGGAGGGCTTrv TCCTCTAAGGGAGGCTTCGTC
Sfrp2 fw ATGTCCGCCTTCGGCTTCCCrv CCTTGGGAGCTTCCTCTGTGGC
Sftpc fw AGCAAAGAGGTCCTGATGGArv GAGCAGAGCCCCTACAATCA
Wisp1 fw GTCCTGAGGGTGGGCAACATrv GGGCGTGTAGTCGTTTCCTCT
Wnt2 fw AGCCCTGATGAACCTTCACAACrv TGACACTTGCATTCTTGTTTCAAG
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Table 4.11: Human quantitative PCR primers
Gene Sequence 5’ - 3’
ACTA2 fw CGAGATCTCACTGACTACCTCATGArv AGAGCTACATAACACAGTTTCTCCTTGA
AQP5 fw TCACTGGGTTTTCTGGGTAGGrv CCTTTGATGATGGCCACACG
AXIN2 fw AGAAATGCATCGCAGTGTGAAGrv GGTGGGTTCTCGGGAAATG
COL1A1 fw CAAGAGGAAGGCCAAGTCGAGrv TTGTCGCAGACGCAGATCC
HOPX fw GCCCCACAGAGGACCAGGTGrv GCTTGGTTAAGCGGAGGAGAG
HPRT fw AAGGACCCCACGAAGTGTTGrv GGCTTTGTATTTTGCTTTTCCA
NKD1 fw CACCCTGTATGACTTTGACAACAACrv CAGAGGAGTCCACCACCTCATAG
PAI1 fw GACATCCTGGAACTGCCCTArv GGTCATGTTGCCTTTCCAGT
PDPN fw GAGAAAGATGGTTTGTCAACAGTGrv GGCGTAACCCTTCAGCTCT
SFTPC fw GCCCAGTGCACCTGAAACGCrv TCTCCAGAACCATCTCCGTGTGT
SNAI1 fw TGTCAGATGAGGACAGTGGGAArv GCCTCCAAGGAAGAGACTGAAGTA
SNAI2 fw TGGCTCAGAAAGCCCCATTAGrv TTTCAGCTTCAATGGCATGGGG
4.1.7 Antibodies
Table 4.12: Primary antibodies for immunofluorescence
Name Source Manufacturer Order nr. Dilutionalpha-SMA (ACTA2) Mouse Sigma-Aldrich; Taufkirchen, Germany A5228 1:500Aquaporin 5 Rabbit Calbiochem, Millipore; Billerica, MA, USA 178615 1:100CD45 Rat BD; San Jose, CA, USA 553076 1:500Collagen 1 Rabbit Rockland; Gilbertsville, PA, USA 600-401-103 1:100E-cadherin (CDH1) Mouse BD; San Jose, CA, USA 610181 1:100Hopx Rabbit Santa Cruz; Santa Cruz, CA, USA sc-30216 1:100Podoplanin Goat R&D; Minneapolis, MN, USA AF3244 1:100Podoplanin Rat Acris; Herford, Germany AM01133PU-N 1:100SFTPC, pro- Rabbit Abcam; Cambridge, UK ab40879 1:500SFTPC, pro- Rabbit Millipore; Billerica, MA, USA AB3786 1:500
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Table 4.13: Primary antibodies for Western Blot
Name Source Manufacturer Order nr. Dilution
Size
[kDa]β-actin Mouse Sigma-Aldrich; TaufkirchenGermany A3854 1:50,000 42β-catenin,active (ABC) Mouse Millipore; Billerica, MA, USA 05-665 1:500 92Aquaporin 5 Rabbit Abcam; Cambridge, UK ab78486 1:5,000 24Aquaporin 5 Rabbit Abcam; Cambridge, UK ab92320 1:1,000 24Hopx Rabbit Santa Cruz; Santa Cruz, CA, USA sc-30216 1:1,000 13Podoplanin Goat R&D; Minneapolis, MN, USA AF3244 1:1,000 40Podoplanin Rat Acris; Herford, Germany AM01133PU-N 1:1,000 37SMAD3,phospho Rabbit Abcam; Cambridge, UK Ab52903 1:1,000 48SMAD2/3 Mouse BD; San Jose, CA, USA 610843 1:1,000 58
Table 4.14: Secondary antibodies for immunofluorescence
Antigen Source Manufacturer Order nr. DilutionGoat-IgG (H+L), Alexa Fluor 488conjugated Donkey Invitrogen Life Technologies;Carlsbad, CA, USA A-11055 1:1,000Goat-IgG (H+L), Alexa Fluor 555conjugated Donkey Invitrogen Life Technologies;Carlsbad, CA, USA A-21432 1:1,000Mouse-IgG, FITC conjugated Goat Dako; Hamburg Deutschland F0479 1:500Mouse-IgG (H+L), Alexa Fluor555 conjugated Rabbit Invitrogen Life Technologies;Carlsbad, CA, USA A-21424 1:1,000Rabbit-IgG (H-L), Alexa Fluor488 conjugated Goat Invitrogen Life Technologies;Carlsbad, CA, USA A-11008 1:1,000Rabbit-IgG (H-L), Alexa Fluor555 conjugated Goat Invitrogen Life Technologies;Carlsbad, CA, USA A-21429 1:1,000Rat IgG (H+L), Alexa Fluor 488conjugated Goat Invitrogen Life Technologies;Carlsbad, CA, USA A-11006 1:1,000Rat IgG (H+L), Alexa Fluor 555conjugated Goat Invitrogen Life Technologies;Carlsbad, CA, USA A-21434 1:1,000
Table 4.15: Secondary antibodies for WB, HRP linked
Antigen Source Manufacturer Order nr. DilutionGoat IgG Rabbit Invitrogen, Life Technologies; Carlsbad, USA 611620 1:15,000Mouse IgG Sheep GE Healthcare; Freiburg, Germany NA931V 1:4,000Rabbit IgG Donkey GE Healthcare; Freiburg, Germany NA934V 1:10,000Rat IgG Goat GE Healthcare; Freiburg, Germany NA935V 1:10,000
Table 4.16: Directly HRP conjugated antibodies for WB
Antigen Source Manufacturer Order nr. Dilutionβ-actin Mouse Sigma Aldrich; Taufkirchen, Germany A3854 1:50,000
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4.1.8 AnimalsFor most of the experiments, and if not stated otherwise, pathogen-free female C57BL/6-N mice(C57BL/6NCrl, Charles River, Germany) in the age of 8-12 weeks were used. Wnt reporter animalswere BAT-GAL (B6.Cg-Tg(BAT-lacZ)3Picc/J), and TCF/LEF-GFP (STOCK Tg(TCF/Lef1-HIST1H2BB/EGFP)61Hadj/J, all The Jackson Laboratory, Maine, USA) [Ferrer-Vaquer, et.al., 2010,Maretto, et.al., 2003]. Mice were housed with water and food ad libitum and could acclimatise forat least one week before used for experiments. All experiments were performed in accordance withthe guidelines of the Ethics Committee of the Helmholtz-Center Munich and approved by theRegierungspräsidium Oberbayern, Germany (project number: 55.2-1-54-2532-168-09).Wnt reporter animals were bred in house with each other, C57BL/6-N, or C57BL/6-J respectively.Tail cuts were used to prepare genomic DNA and normal PCR was run for genotyping. Onlypositively tested mice in the age of 8-12 weeks were used for the experiments.
4.1.9 Human TissueThe experiments with human tissue were approved by the Ethics Committee of the Ludwig-Maximillian University Munich, Germany (project-nr. 455-12). The Asklepios Biobank for LungDiseases, Gauting, Germany (project-nr. 333-10) provided all samples. Written informed consentwas obtained from all subjects. Tumour-free tissue from patients that underwent lung tumourresection was used. Patients were either with or without diagnosed COPD. All of them had asmoking history and relevant characteristics are shown in Table 4.17.
Table 4.17: Characteristics of the human patients used for 3D-LTC
Nr. Gender Age[years]
Smoking
status Pack years (PY) FEV1 FEV1/FVC
GOLD
stage1 male 73 ex-smoker 80 PY, cessation 12 y 105 86 no2 male 60 ex-smoker n.d. 122 84 no3 male 51 active smoker 40 PY 106 73 no4 male 68 smoker n.d. 62 49 II5 male 63 active smoker 40-60 PY 85 70 I6 male 73 ex-smoker 40 PY, cessation 5-10 y 81 82 no7 female 72 ex-smoker 20-40 PY, cessation 10-20 y 47 51 III8 female 70 active smoker 40-60 PY 52 61 II9 male 78 ex-smoker n.d., cessation > 20 y 89 59 I10 male 58 active smoker 40-60 PY 60 68 II11 female 64 active smoker n.d. 114 89 no12 male 60 active smoker 50 PY 101 71 no13 female 68 ex-smoker 40-60 PY, cessation 1-5 y 83 74 no14 female 78 active smoker 50 PY 85 67 I15 male 66 ex-smoker 70 PY, cessation 12 y 106 86 no16 male 59 active smoker 80 PY 85 67 I
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4.2 MethodsAll microbiology and molecular biology methods were performed according to common goodlaboratory practice.
4.2.1 Animal model of emphysema induced by elastase instillationTo induce emphysema, mice were anaesthetised with a mixture of medetomidine (0.2 mg/ml),midazolam (2.0 mg/ml), and fentanyl (0.02 mg/ml) (MMF). Porcine pancreatic elastase wasdissolved in sterile phosphate-buffered saline and applied oro tracheally (80 U/kg body weight).Control mice received 80 µl sterile phosphate-buffered saline. Animal behaviour and weight wereobserved every day until day three and every other day afterwards. Mice were breathing heavilyand were hardly moving within the first 24 h after elastase instillation. Thereafter, no abnormalbehaviour was observed and a difference between control and emphysematous animals was notvisible from day two on. Diseased mice significantly lost weight after induction of emphysema overthe whole time course (see chapter 3.1, Figure 4.1). Seven days after the instillation, when theinflammatory reaction was gone and emphysema had developed, 3D-LTC were generated. Lungsfrom healthy (PBS instilled) animals were filled with 1.4 ml while lungs from emphysematous(elastase instilled) animals needed to be filled with approximately 1.7 ml of agarose, due to theemphysema and the resulting increase in lung volume.
Figure 4.1: Weight of emphysematous mice was significantly decreased at all time points.Weight of healthy and emphysematous mice at different time points after instillation with PBS or porcine pancreaticelastase. n=75-130. *: p<0.05, **: p<0.01, ***: p<0.001, one way ANOVA with Bonferroni post-test.
4.2.2 Generation of 3D-LTC (PCLS)An overview of the process of the generation of 3D-LTC, later on also named “slices”, is shown inFigure 4.2. The whole procedure was performed under sterile conditions. Surgical instruments(scissors and forceps) were from Fine Science Tools (Heidelberg, Germany).
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Figure 4.2: Overview of the generation of the 3D-LTC from murine and human samples.Murine and human lung tissue was filled with low-melting agarose and 3D-LTC were cut using a vibratome. 3D-LTCwith intact 3D architecture were cultivated for up to seven days and used for further analysis.
4.2.2.1 Generation of 3D-LTC from murine lungsFor the murine 3D-LTC mice were anaesthetised with a mixture of ketamine and xylazinhydrochloride. After disinfection of the fur by 80% ethanol the skin was opened with scissors fromthe abdomen to the trachea. Afterwards, the throat was opened with blunt forceps and thesurrounding muscles were removed. Two threads were placed below the trachea and a smallincision was made for intubation with a cannula. Thereafter, the cannula was fixed with one of thethreads and the abdomen was dissected with blunt scissors to expose the inner organs. Mice werekilled by exsanguation via the Vena cava. After this, the diaphragm was dissected leading topneumothorax and the thorax was opened. The thymus glandwas removed with blunt forceps andthe lung was perfused via the right ventricle of the heart with sterile 0.9% NaCl. Broncho-alveolar-lavage (BAL) was taken afterwards with 2x 500 µl 0.9% NaCl and centrifuged at 5,000 g for 5 min.Supernatant was transferred into a new vial and BAL cells as well as BAL supernatants were snapfrozen in liquid nitrogen and stored at -80°C. Thereafter, the lungs were inflated with pre-warmed(37°C) 2% agarose in sterile cultivation medium (4.1.3) without FCS. 1.4 ml agarose was used forhealthy animals while 1.7 ml was needed for emphysematous mice. The trachea was closed withthe second thread after agarose instillation and lung and heart were excised en bloc. After this, thelung was transferred into a tube with cultivation medium and cooled on ice for 10 min, to allowgelling of the agarose. The lobes were separated and cut with a vibratome to a thickness of 300 µm.The 3D-LTC were cultivated for up to five days under submerged conditions. Only the periphery of
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the left lung and the superior and inferior lobe of the right lung were used for slicing. The leftoverof these lobes were used for immunohistochemistry. The other two lobes were snap frozen inliquid nitrogen and stored at -80°C. These samples served as “d0” controls for Western blot.To make sure that the inflation material will not stick to the lung tissue, as it might be the case forthe agarose, other materials were used for inflation of the lungs as well. 2% sodium-alginate whichwas inflated and cross-linked by transferring the whole lung into a 100 mM calcium-chloridesolution (in PBS) for 10 min, which was proven by water soluble tetrazolim salt (WST-1) assay tobe non-toxic to the cells, turned out to be not suitable. 3D-LTC collapsed during cultivation andpermeabilisation for immunofluorescence staining making further imaging impossible. Ultra lowmelting agarose (tested 2-4%), which has an extreme low melting point and therefore will getdissolve in the cultivation medium and get released from the tissue during cultivationmore readily,turned out to be not stiff enough to prepare 3D-LTC.
4.2.2.2 Generation of 3D-LTC from human lung segmentsFor the human 3D-LTC, lung segments without tumours from patients undergoing lung resectiondue to cancer were cannulised via the remaining bronchus and filled with warm agarose directlyafter excision. The amount of agarose was adjusted to the size of the tissue and ranged between 20and 80ml. The bronchus was closed afterwards with a thread to avoid reflux. Lung segments werecooled on ice for 30 min to allow gelling of the agarose (3%), cut into pieces of an cross sectionalarea of approximately 2.5 – 4 cm2 before they were cut with the vibratome to a thickness of 500 µm,and cultivated for up to 5 days under submerged conditions.
4.2.3 RNA expression analysis4.2.3.1 RNA isolationFor total RNA isolation the Fibrous Tissue Kit was used with slight adaptations of the protocolprovided by the manufacturer. Slices were washed twice with PBS, snap frozen in liquid nitrogenand kept at -80 °C until isolation was done. Three to five slices per treatment and time point fromdifferent regions of the lung (as suggested by Liberati et al. [Liberati, et.al., 2010]) were pooled.Only slices from the periphery of the lung containing no main bronchi were included. Slices wereput into a tube with a 9mm steel ball and put into a Micro-Dismembrator S for 2x 30 s at 3,000 rpm.The device and tubes were cooled with liquid nitrogen in between to avoid sample warming. Thepowder was lysed with 1 ml lysis buffer containing 12 µl TCEP for 1 h on ice. Afterwards sampleswere incubated with 25 µl proteinase K for 10min on ice. For each sample 2 preclear columns wereused. 550 µl were put onto the column and centrifuged at 400 g for 60 s. The flow through of thefirst preclear column was put onto the purification column and centrifuged at 13.000 g for 60 s.This flow through was discarded. The flow through of the second preclear column was put ontothe same purification column and centrifuged at 13.000 g for 60 s. Wash step 1 was done twice
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with 300 and 100 µl respectively with centrifugation at 13.000 g for 60 s in between. The columnwas put into a new collection tube and DNase digestion (50 µl of DNase) was done on the columnfor 20-30 min. Columns were washed twice with 200 µl DNase Wash with centrifugation at13.000 g for 60 s in between and columns were put afterwards into a new collection tube. Columnswere washed twice with 200 µl Wash 2 solution with centrifugation at 13.000 g for 60 s in betweenand columns were put afterwards into a new collection tube. Columns were centrifuged at 13.000 gfor 60 s without solution on top (“dry”) and afterwards put into the elution tube. RNA elution wasdone with 40 µl elution buffer at 13.000 g for 60 s. After the elution, the flow through was put againonto the column and centrifuged at 13.000 g for 60 s. RNA was kept on ice and concentration wasdetermined with a NanoDrop 1000 spectrophotometer using RNase/DNase free water or elutionbuffer as blank. For the human samples the quality of the RNA was checked with a Bioanalyzerusing the Agilent RNA 6000 Nano Kit according to the protocol provided by the manufacturer. Onlysamples with a RNA integrity number above 5 (in general 7-8) were used for further analysis.
4.2.3.2 cDNA synthesis by reverse transcription1 µg of RNA in 20 µl RNase/DNase free water was denatured at 72 °C for 10 min then chilled onice. Transcription was carried out by adding the reagents described in Table 4.18. Incubation at20 °C for 10min was followed by 43 °C for 75 min and 99 °C for 5 min in a Mastercycler. cDNA wasdiluted 1:5 with water and stored at -20 °C.
Table 4.18: cDNA synthesis by reverse transcriptionReagent StockConcentration Final concentrationin 40 µl Volume10x Buffer II 100 mM 10 mM, 1x 4 µlMgCl2 25 mM 5mM 8 µldNTPs 10 mM 0.5 mM 2 µlRandom hexamers 50 µM 2.5 µM 2 µlRnase inhibitor 5 U/µl 0.25 U/µl 1 µlMuLV reverse transcriptase 50 U/µl 2.5 U/µl 2 µlH2O 1 µltotal volume with addition of 1 µg RNA (in 20 µl) 40 µl
4.2.3.3 Quantitative PCR (qPCR)In general, 12.5 ng/µl cDNA were used for qPCR. The composition of the qPCR master mix is listedin Table 4.19. All qPCR assays were performed in duplicates with the reaction conditions shown inTable 4.20. For standardization of relative mRNA expression, human and mouse hypoxanthine-guanine phosphoribosyltransferase (HPRT) primers were used. Relative transcript abundance ofa gene is expressed in ΔCp values (ΔCp = Cpreference – Cptarget). Relative changes of mRNA levels ofcontrol/mRNA levels of treatment are presented as ΔΔCp values (ΔΔCp = ΔCptreated – ΔCpcontrol).
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Table 4.19: Master mix for quantitative PCR
Reagent Stock concentration Final concentration VolumeLight Cycler 480 SybrGreen l Master Mix 2x 1x 10 µlPrimer mix 10 µM each 0.5 µM 1 µlH2O 4 µlcDNA 5 ng/µl 1.25 ng/µl 5 µltotal 20 µl
Table 4.20: Reaction conditions for quantitative PCR
Repetitions Cycle step Temperature Time1x Initial denaturation 95 °C 5 min45x Denaturation 95 °C 5 sAnnealing 59 °C 5 sElongation 72 °C with single acquisition 10 s1x Melting curve 95 °C 5 s1x 60 °C 1 min1x 60 °C -95 °C with continuous acquisitionCooling 4 °C on hold
4.2.4 GenotypingTail cuts were used to prepare genomic DNA by lysis with 1x PBND buffer at 55 °C for 4 h with lightshaking. Primer sequences are shown in Table 4.9. Normal PCR was run according to the programsshown inTable 4.22 and Table 4.23. After the PCR DNA fragments were separated by electrophoresis usinga 2 % agarose gel supplemented with 1x SybrSafe. 10 µl of the DNA samples and 5 µl of the 100 bpDNA ladder (Table 4.6) were loaded per pocket. Separation was done in 1x TAE buffer (4.1.3) byapplying 80 V for 1 h. The DNA bands were visualized by using the XcitaBlue™ Conversion Screenfrom the ChemicDoc with illumination at 470 nm.
Table 4.21: PCR reaction mixture for genotyping
Reagent Concentration Volume Final concentrationGoTaq G2 Hot Start Green Master Mix 2x 10 µl 1xforward primer transgene 100 µM 0.05 µl 250 nMreverse primer transgene 100 µM 0.05 µl 250 nMforward primer internal control 100 µM 0.05 µl 250 nMreverse primer internal control 100 µM 0.05 µl 250 nMtemplate (genomic DNA) variable 0.5 to 2 µl variableUltraPure DNase/RNase-Free Distilled Water up to 20 µl
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Table 4.22: PCR reaction conditions for genotyping of the TCF-LEF-EGFP mice
Repetitions Cycle step Temperature Time1x Initial denaturation 94 °C 3 min
35x Denaturation 94 °C 30 sAnnealing 60 °C 30 sElongation 72 °C 30 s1x Final elongation 72 °C 2 minCooling 4 °C on hold
Table 4.23: PCR reaction conditions for genotyping of the BAT-GAL and TOP-GAL mice
Repetitions Cycle step Temperature Time1x Initial denaturation 94 °C 3 min
12x Denaturation 94 °C 20 sAnnealing 64 °C, with -0.5 °C per cycle 30 sElongation 72 °C 35 s
25x Denaturation 94 °C 20 sAnnealing 58 °C 30 sElongation 72 °C 35 s1x Final elongation 72 °C 2 minCooling 4 °C on hold
4.2.5 Viability and proliferation assays4.2.5.1 Live/Dead assayLive/Dead staining was performed by using the LIVE/DEAD® Viability/Cytotoxicity Kit *formammalian cells*. Lung tissue cultures were punched to a diameter of 4 mm using a biopsy punchand incubated with cultivation medium supplemented with 2 µM calcein AM and 4 µM ethidiumhomodimer-1 for 40 min. Afterwards they were washed twice with PBS, fixed with 4%paraformaldehyde (PFA), and mounted onto glass slides with fluorescent mounting medium.Edges of the cover slips were sealed with nail polish. Calcein AM is converted into the greenfluorescent calcein by serum esterases which are only active in viable cells, leading to a greenfluorescent cytoplasm. Ethidiumhomodimer-1 can only enter cells with non-intact cell membraneswhere it binds to the DNA and leads to a 40 fold increase of red fluorescence in the nucleus. By this,viable cells are identified via the green fluorescent cytoplasm while dead cells are indicated by ared nucleus.
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4.2.5.2 WST-1 assayTissue cultures from the periphery of the lung were punched to a diameter of 4 mm and incubatedwith 15 µl WST-1 per ml of cultivation medium for mouse slices or 30 µl WST-1 per ml cultivationmedium for human slices. WST-1, is a tetrazolium salt, which is converted by the mitochondria ofthe cells. The conversion of the dye gives a linear measurement for mitochondrial activity. A highermitochondrial activity can result either from an increased number of cells, and thereby a highernumber of dye-converting mitochondria, or from higher metabolic activity. Assuming that themean number and activity of mitochondria per cell are comparable, this assay can be used as ameasure of cellular viability.After 2 h 150 µl supernatant were measured in a plate reader at 450 nm. Reference measurementat 690 nm was subtracted. For each time point and treatment at least 3 punched slices fromdifferent mice, or different lung areas of human slices, were measured. As absorbancemeasurements for the human slices varied between the different patients, the mean value of thecontrol treatment at d0 was set to 100% for each patient to make comparison possible.
4.2.5.3 BrdU assayPunched lung slices (diameter 4 mm) were incubated with BrdU labelling medium (preparedaccording to the manual provided by the manufacturer) for 24 h at different time points of thecultivation (d0=labelling of the cells for 24 h from d0 on, d1=labelling of the cells for 24 h from d1on, d3=labelling of the cells for 24 h from d3 on, d5=labelling of the cells for 24 h from d5 on). Bythis, the yimidine analog BrdU is incorporated in place of thymidine into the DNA of proliferatingcells. With an antibody against BrdU the amount of this incorporation can be quantified based onELISA technique. The ELISA to determine BrdU incorporation was performed according to themanual provided by the manufacturer. Values were presented relative to d0.
4.2.5.4 Lactate dehydrogenase (LDH) assayLDH is released by the cells into the supernatant. This release is increased when the cells aredamaged, as their cell membrane gets leaky. For this reason, the LDH release is normally used as ameasurement for toxicity. Punched lung slices (diameter 4 mm) were incubated with 200 µl offresh cultivation medium 24 h hours before the measurement was done. Cell culture supernatantwas taken and cleared from cell debris by centrifugation. Afterwards, 100 µl supernatant wasincubated with 100 µl reaction solution (according to protocol provided by the manufacturer:2.5 µl catalyst mixed with 112.5 µl dye solution per sample) in a 96 well-plate for 15-30 min in thedark at room temperature. Cultivation medium incubated the same time without slices was use asblank. Reaction was stopped with 50 µl of 1 M HCl and absorbance was measured in a plate readerat 490 nm. Reference measurement at 690 nm was substracted.
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4.2.6 Proteinbiochemistry4.2.6.1 Protein isolation and concentration determinationTissue slices were washed twice in PBS before they were snap frozen in liquid nitrogen and storedat -80 °C. Three to four slices were pooled per treatment and time point and pulverized with aMicro-Dismembrator S the same way as for RNA isolation (4.2.3.1). The powder was lysed with300-400 µl T-PER-buffer supplemented with phosphatase and protease inhibitors (1 tablet eachper 10ml buffer). Afterwards, samples were frozen at -80 °C and thawed on ice. Thereafter, proteinextracts were clarified by centrifugation at 13,000 g at 4 °C and stored at -80 °C. Protein contentwas measured using the Pierce™ BCA Protein Assay Kit according to the protocol provided by themanufacturer.
4.2.6.2 Protein analysis with Western Blot15 µg of protein lysate were mixed with Laemmli loading buffer and T-PER buffer for equalvolumes. SDS polyacrylamide gel concentration was adjusted to the size of the protein to bedetected (ranging from 6 to 15%). Electrophoresis was done with 70 V for 15 min and 120 V forfurther 60-90 min in SDS-PAGE Running Buffer. Proteins were transferred to nitrocellulosemembranes with 300 mA for 90 min at 4 °C using 1x transfer buffer. Unspecific antibody bindingwas blocked with 5% non-fat milk for 1 h. Blots were incubated with primary antibodies at 4 °Cover night or for 1.5 h at RT with light shaking. After three washing steps with TBST at RT blotswere incubated with secondary antibodies for 1.5 h at RT. Enhanced chemiluminescence was usedto visualize proteins and the signals were measured either using the ChemiDoc or an x-ray film,which was automatically developed with the film developer Curix 60. The used antibodies andconcentrations are listed in Table 4.13, Table 4.15, and Table 4.16.
4.2.6.3 Enzyme-linked immunosorbant assay (ELISA)SFTPC protein concentrations in protein lysates from murine and human 3D-LTC were determinedusing a mouse/human SFTPC ELISA from Cusabio according to protocol provided by themanufacturer. Samples were measured in triplicates. For murine samples 5 ng and for humansamples 2 ng of protein was used. Results were presented as percentage of SFTPC protein to totalprotein.
4.2.7 HistologyDifferent stainings were conducted for histological analysis. Samples for staining withHaematoxylin & Eosin, Masson-Trichrome and Elastin (see 4.2.2) were fixed in 4% PFA over nightand transferred into paraffin with a Microm STP 420D machine according to the protocol fromTable 4.24. Afterwards, samples were embedded into paraffin blocks using the Microm EC350 and
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stored at 4°C. 2-3 µm thin sections were cut with a Hyrax M55 microtome and fitted onto glassslides.
Table 4.24: Protocol used for paraffin embedding of tissue samples
Reagent Time4% PFA 60 min4% PFA 60 min50% ethanol 60 min70% ethanol 60 min96% ethanol 60 min96% ethanol 60 min100% ethanol 60 min100% ethanol 60 minXylene 60 minXylene 60 minParaffin 30 minParaffin 45 minParaffin 45 minParaffin 45 min
4.2.7.1 Haematoxylin & Eosin (H&E) stainingParaffin sections were deparaffinised and rehydrated before staining according to the followingprotocol (Table 4.25). After the last step glass slides were covered with coverslips using HI-MOmounting medium.
Table 4.25: Protocol used for H&E staining
Reagent TimeXylene 5 minXylene 5 min100% ethanol 1 min100% ethanol 1 min90% ethanol 1 min80% ethanol 1 min70% ethanol 1 minDistilled water FlushingHeamatoxylin 5 minTap water FlushingHCl-ethanol (0.3% in 70% ethanol) Up to 1 minTap water 10-15 minDistilled water FlushingEosin (0.5 g in 70% ethanol) 8 minDistilled water Flushing70% ethanol Flushing
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80% ethanol Flushing90% ethanol Flushing100% ethanol FlushingXylene 5 minXylene 5 min
4.2.7.2 Masson-Trichrome (MTC) stainingMasson-Trichrome staining was performed by Maria Neuner according to the protocol shown inTable 4.26.
Table 4.26: Protocol used for Masson-Trichrome staining
Reagent TimeXylene 5 minXylene 5 min100% ethanol 1 min100% ethanol 1 min90% ethanol 1 min80% ethanol 1 min70% ethanol 1 minWeigerts-staining solution 10 minTap water 3 min, 1x exchange the waterHCl-ethanol (0.3% HCl in 70% ethanol) Up to 1 minDistilled water FlushingPonceau-fuchsin 6 minDistilled water Flushing1% acetic acid Flushing, 1x exchangeDistilled water FlushingPhosphomolybdate solution 5 min1% acetic acid Flushing, 1x exchangeDistilled water FlushingLight green SF (20 mg/l in 0.2% acetic acid) 8 min1% acetic acid Flushing, 1x exchangeDistilled water Flushing70% ethanol Flushing80% ethanol Flushing90% ethanol Flushing100% ethanol FlushingXylene 5 minXylene 5 min
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4.2.7.3 Elastin stainingElastin staining was performed by Maria Neuner with a modified Hart’s elastic staining protocol(Table 4.27).
Table 4.27: Protocol used for elastin staining
Reagent TimeXylene 15 minXylene 15 min100% ethanol 5 min100% ethanol 5 min90% ethanol 5 min70% ethanol 5 min70% ethanol 5 minDistilled water (2x) Flushing0.25% potassium permanganate 5 minDistilled water (several) Flushing5% oxalic acid dihydrate 5-10 sTap water 5 min with flushingDistilled water FlushingResorcsin-fuchsin(1:10 in 70% ethanol with 20 mM HCl) Over night in the darkTap water 15 min with flushing0.25% tartrazine (in 2.5 mM acetic acid) 90 s70% ethanol Flushing70% ethanol Flushing96% ethanol Flushing96% ethanol Flushing100% ethanol 5 min100% ethanol 5 minXylene 5 minXylene 5 min
4.2.7.4 LacZ stainingThe tissue cultures were washed twice with PBS and prefixed for 10 min in 4% PFA. After 3washing steps with PBS the slices were once rinsed with LacZ staining solution to preventprecipitations. Afterwards, the tissue was incubated in X-Gal/LacZ staining solution in the dark at37°C over night leading to blue staining in the cells in which canonical Wnt signalling was activated.Two further washing steps with PBS were followed by mounting onto glass slides with HI-MOmounting medium. Staining was evaluated via brightflield microscopy.
MATERIALS ANDMETHODS | 39
4.2.7.5 ImmunofluorescenceTissue cultures were washed twice with PBS and fixed with acetone/methanol 50/50 v/v for20 min. After washing three times with 0.1% BSA in PBS the tissue was punched to a diameter of4 mm by using a biopsy punch, and incubated with primary antibody over night at 4 °C. Fivewashing steps with 0.1% BSA in PBS were followed by incubation with secondary antibodies for1 h. Thereafter, samples were washed three times with 0.1% BSA in PBS and cell nuclei werestained with 0.5 µg/ml DAPI for 5 min. After three washing steps with 0.1% BSA in PBS sampleswere fixed again with 4% PFA for 30 min and mounted onto microscopy slides with fluorescencemounting medium. Staining was evaluated via confocal microscopy. 3D reconstruction wasconducted using the IMARIS software. Antibodies that were used are listed in Table 4.10 and Table4.12.
4.2.8 Live cell imagingConfocal time-lapse microscopy was implemented on an LSM710 system (Zeiss) containing aninverted AxioObserver.Z1 stand. 3D-LTCwere incubated with primary antibodies in the cultivationmedium over night and nuclei were stained with Hoechst for 30 min prior to observation. Afterpunching to a diameter of 6 mm, 3D-LTC were transferred to imaging plates and fixed to avoidmovements during imaging. They were kept submerged in DMEM/HAM’s F12 medium containing0.1% FCS and 15 mM HEPES during the whole period of observation. Imaging of the 3D-LTC wasperformed in a PM S1 incubator chamber (Zeiss) at 37°C. Acquisition of the 3D-LTC started within30 min after their transfer to the imaging plates. Z-stacks (50-100 µm) were acquired with an ECPlan-Neofluar DICII 20x/ 0.8 NA objective lens (Zeiss) in 30 minutes intervals up to 24 h. Theautomated time-lapse microscope was operated by ZEN2009 software (Zeiss). The confocal 4Ddata sets were imported into Imaris 7.4.0 software (Bitplane) and processed by applying a volumerendering algorithm.
4.2.9 Statistical AnalysisAll values are shown as mean with standard deviation. For comparison of two groups unpaired t-test with Welch‘s correction or two tailed, paired t-test (for paired observations) was used. Morethan two groups were compared with ANOVA and Bonferroni post-test. A p-value lower then 0.05was considered statistically significant. All statistical analyses were performed with the GraphPadPrism Software.
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5 RESULTS
5.1 Characterization of 3D-LTC from healthy/non-COPD tissue over timeIn standard 2D cultures, where cells are grown for instance in monolayers, cells normally do notlack oxygen and/or nutrients. This dramatically changes when cells are grown in multilayers andin three dimensional tissues where diffusion gradients may lead to shortage of oxygen and/ornutrients in certain regions of the culture thereby inducing alterations in gene expression due tothe adaptation of the cells to the oxygen- and/or nutrient-deprived environment or even cell deathby induction of apoptosis or necrosis [Macintosh, et.al., 2013, Poon, et.al., 2010]. To exclude thatsuch oxygen and/or nutrient shortage occurs in the 3D-LTC, their cell viability and proliferationwere evaluated. A combination of different methods, such as live cell imaging, Live/Dead staining,WST-1 conversion, and BrdU incorporation, was conducted to confirm cell viability andproliferation over seven days.First, live cell imaging was applied for analysing cell viability. A time-laps video, depicted as singleimages, from day seven of the cultivation of a 3D-LTC from a moue lung showed sustained ciliarybeating of a bronchial epithelial cell (Figure 5.1). This gave first evidence that cells inside the tissueculture are viable and remain functional until day seven.
Figure 5.1: Ciliary beating was sustained in 3D-LTC from healthy animals until day seven.Consecutive live cell imaging pictures of a bronchial epithelial cell in a 3D-LTC from a healthy mouse on day seven ofculture. Images were taken with the “maximum speed” method (taken as fast as possible).Live cell imaging, conducted until day seven showed fast cellular movement of single cells insidethe 3D-LTC. These cells seemed to be located on top of the alveolar matrix assuming to be alveolarmacrophages/leucocytes. With standard light microscopy, only a low resolution in z-direction(height) could be achieved. To improve resolution, determine cell type specificity, and to evaluateindividual cell migration, immunofluorescence labelling of the ECM (collagen I), leucocytes (CD45),and cell nuclei in general (Hoechst) was conducted (Figure 5.2). CD45 labeled and other cells(identified by Hoechst stain only) were moving inside the 3D-LTC during the whole period ofobservation (12 h starting on day two of the cultivation). This added evidence that the cells inside
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the 3D-LTC remained vital over time. To further prove viability Live/Dead staining andmitochondrial activity measurements were conducted, showing positive staining for viable cellsduring five days of cultivation and increased mitochondrial activity from day one to day three,being stable at day five. The detailed results from 3D-LTC from healthy animals will be shown inFigure 5.5 and Figure 5.6 together with the results from emphysematous animals since no majordifference were observed.
Figure 5.2: Cellular movements in 3D-LTC showing that cells remain viable.Live cell imaging picture series of amurine 3D-LTC showingmigrating cells over time. Images were taken every 15minon day two for 12 h. Pictures are shown for 0-7 h. The extracellular matrix was stained with collagen I (green),leukocytes with CD45 (red), and nuclei in general with Hoechst (blue). Arrows point to regions where cellularmovements occurred. Scale bar 100 µm.Next, the proliferative capacity of the cells was analysed by incorporation of BrdU, to get moreinsight into cellular turnover. Cells were labelled for 24 h at different time points (d0, d1, d3, andd5). Afterwards, an ELISA was conducted and quantitative measurement over the time wasevaluated. Proliferation in the 3D-LTC followed the same profile for both 0.1% and 10% FCScultivation medium showing a significant increase on day three. After that peak, proliferation stilloccurred but was reduced compared to day three. 10% FCS led to a higher proliferation ratesupporting the cell viability data from above (Figure 5.3). Cells inside the 3D-LTC proliferated inthe first days of cultivation leading to more viable cells. After this initial peak of proliferation, 3D-LTC stayed stable with ongoing, but reduced proliferation compared to the early time points. Inconclusion, 3D-LTC were viable and exhibited proliferative capacity until day five.
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Figure 5.3: Proliferation of the cells in 3D-LTC peaked at day three (=day four) of culture.Quantitative analysis of the proliferation of cells in murine 3D-LTC cultivated with A) 0.1% FCS and B) 10% FCScultivation medium. n=11-24. *: p<0.05, **: p<0.01, ***: p<0.001, #: compared to d0, one way ANOVA with Bonferronipost-test.The next step was to adapt the method of 3D-LTC to human tissue. To characterize viability duringcultivation Live/Dead staining and mitochondrial activity were assessed in 3D-LTC from humannon-COPD patients. Similar results were obtained compared to the murine 3D-LTC and will beshown in detail in Figure 5.8 and Figure 5.9 together with the results from COPD tissue slices sinceno major differences were observed.The sustained ciliary beating, the cellular movements during live cell imaging, the positive Live-staining, and the mitochondrial activity as well as the proliferation data show that 3D-LTC fromhealthy murine and human non-COPD tissue maintain their viability during cultivation.
5.2 Characterization of 3D-LTC from diseased lung tissue specimenAn animal model for the emphysematous changes seen in COPD is oro tracheal instillation ofporcine pancreatic elastase (PPE) in the range of 40-120 U/kg mouse. In addition to MMP-2, -9,and -12, elastase is known to be the key elastolytic enzyme contributing to emphysema [Shapiro,2002]. Peribronchial remodelling, normally seen in COPD, cannot be observed [Antunes, et.al.,2011]. The elastase-induced emphysema model benefits from lower costs and more efficientgeneration of emphysema compared to other models (e.g. cigarette smoke exposure). Theapplication of elastase oro tracheally is very easy and the mortality of the treated animals is low(we observed less than 10% mortality in total). In general, PPE is applied only once, resulting inprogressive emphysema development while the applied PPE dose determines emphysemaseverity [Andersen, et.al., 2012, Inoue, et.al., 2003, Ito, et.al., 2005, Kononov, et.al., 2001, Lucey,et.al., 1998]. In the first few days after administration, a temporary, injury-induced inflammationresponse occurs with an increase in inflammatory cells in the bronchoalveolar lavage fluid (BALF),which decreases after approximately five days. Even though inflammation is not recurring in thismodel compared to cigarette smoke exposure, emphysema development increases over time. Inthis thesis, the elastase-induced emphysema model on day seven after elastase application wasused.
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5.2.1 Morphology and viability of 3D-LTC after elastase induced emphysemaNext, 3D-LTC from diseased mouse tissue were characterized regarding their morphologicalcharacteristics and viability in culture. Cultures of 3D-LTC from healthy and emphysematous micewere imaged after histologic and immunofluorescence staining. Emphysema was clearly visible inthe 3D-LTC fabricated seven days after elastase administration. Airspace enlargement and alveolardestruction was also clearly distinguishable. Less elastin (black) was seen in the elastin stainingsupporting loss of elastin fibres in emphysematous tissue (Figure 5.4A). Immunofluorescenceimages in Figure 5.4B revealed that specific extra-cellular matrix components like collagen I couldbe imaged and the antibodies used reached the whole interior of the 3D-LTC, staining the middleof the cultures as well (compare definition of middle plane Figure 5.5A). Single cell types, such asCD45- (leucocytes), pro-SFTPC- (ATII cells), aquoporin5-positive cells (AQP5, ATI cells), as well aspositive staining for podoplanin (PDPN, ATI cells), and cellular junctions (shown for E-cadherin,CDH1) was obtained in the 3D-LTC (Figure 5.4C). These data clearly indicate that diseased mousetissue morphology and structure can be well maintained by 3D-LTC and validate this technologyfor the use of diseased lung tissue.
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Figure 5.4: Emphysematous changes can be evaluated in the 3D-LTC.A: H&E, Masson Trichrome, and Elastin staining of 3D-LTC from healthy and emphysematous mice. Scale bar 100 µm.B: 3D reconstruction of immunofluorescence staining of collagen I. Scale bar 100 µm. C: Immunofluorescence stainingof extracellular matrix with collagen I, specific cell types with CD45 (leucocytes), pro-SFTPC (ATII), aquaporin 5 (ATI),as well as podoplanin (ATI), and cellular junctions with E-cadherin antibodies. Scale bar 50 µm, insert: 100 µm. Thenuclei were stained with DAPI.Live/Dead staining was applied to investigate cell viability in more detail. The whole height(300 µm) of the 3D-LTC was investigated and different regions (top, middle, and bottom plane)were examined (Figure 5.5). Dead cells, indicated by a red nucleus, were nearly absent in the
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middle of the 3D-LTC and were mainly seen at slice margins (top and bottom plane). Over thewhole period of cultivation, no differences in cell viability, especially no increase in dead cells, wasdetected, however, a slight decrease in fluorescence intensity of the green dye, indicative for viablecells, from day five on was observed (Figure 5.5B).
Figure 5.5: 3D-LTC from healthy and emphysematous mice stayed viable over five days of cultivation.A: Scheme of the different regions of the 3D-LTC referred to as top, middle, and bottom plane. B: RepresentativeLive/Dead confocal images (cut view) of the different planes of the 3D-LTC from healthy and emphysematous mice atthe indicated time points. Healthy cells are indicated by green cytoplasm (arrows) and dead cells by red nucleus(arrowheads). Scale bar 50 µm.The third method to test for cell viability was incubation of 3D-LTC with WST-1 supplementedcultivation medium. Mitochondrial activity was significantly increasing from day one to day threeand stayed stable until day five (Figure 5.6). Measurement values from emphysematous mice wereslightly lower but exhibited the same kinetics. No significant difference in WST-1 conversion atdifferent time points was observed between 0.1% FCS and 10% FCS medium (data not shown).Furthermore, no significant difference between WST-1 conversion of 3D-LTC from healthy mice(PBS instilled) compared with age matched non-treated mice was seen (data not shown).
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Figure 5.6: WST-1 conversion increased until day three in 3D-LTC from healthy and emphysematous mice.WST-1 conversion of the cells in 3D-LTC from healthy and emphysematous mice cultivated for five days. n=6-11. *:p<0.05, **: p<0.01, one way ANOVA with Bonferroni post-test.The WST-1 measurement data confirmed the results from the Live/Dead staining and live cellimaging, showing that in 3D-LTC from both healthy and emphysematous mice cells stay viableduring the cultivation. Whether cell numbers increased over time, or if the cells simply becameactivated leading to the increase in WST-1 conversion could not be determined with this method.
5.2.2 Morphology and viability of 3D-LTC from human patientsThemajor benefit of 3D-LTC is the possibility to generate them from any species. Lung tissue fromhuman patients undergoing lung resection surgery due to lung cancer was used to apply themethod as a translational approach and for use as a preclinical testing tool. 3D-LTCwere generatedfrom human COPD and non-COPD samples as described in chapter 4.2.2 and analysed regardingmorphology and viability, as well. Lung tissue structure, analysed by haematoxylin & eosin stainingrevealed the emphysematous changes occurring in these lung specimens. Samples from COPDpatients had increased alveolar airspaces and showed alveolar destruction (Figure 5.7A). By usageof a collagen I immunofluorescence staining 3D reconstruction of this ECM protein networkstructure was possible (Figure 5.7B). Similar to the murine samples a broad range of markers wasaccessible for analysis by immunofluorescence staining, as shown for instance for pro-SFTPC,podoplanin, and E-cadherin (Figure 5.7C).
RESULTS  47
Figure 5.7: Emphysematous changes can be evaluated in 3D-LTC from human patients.A: H&E staining of 3D-LTC from non-COPD and COPD patients. Inserts are showing a higher magnification. Scale bars100 µm. B: 3D reconstruction of immunofluorescence staining of collagen I. Scale bar 100 µm. C: Immunofluorescencestaining of pro-SFTPC, podoplanin, and E-cadherin. Scale bar 50 µm. The nuclei were stained with DAPI.Viability of the human 3D-LTC was analysed by Live/Dead staining and WST-1 conversion.Differences in Live/Dead staining between non-COPD and COPD patients was not visible. In themiddle plane, only few cells were marked by red staining and therefore considered as dead cells(Figure 5.8).
48  RESULTS
Figure 5.8: 3D-LTC from human patients stayed viable over five days of cultivation.Live/Dead staining, confocal images (cut view) of the different planes of 3D-LTC from human patients at the indicatedtime points. Healthy cells are indicated by green cytoplasm (arrows) and dead cells by red nuclei (arrowheads).Mitochondrial activity of human 3D-LTC showed a similar increase, as seen for the murine samples,being significant until day three and stable afterwards. No significant difference was observedbetween COPD and non-COPD samples for the analysed time points (Figure 5.9).
Figure 5.9: WST-1 conversion increases until day three in 3D-LTC from human patients.WST-1 conversion of the cells in 3D-LTC from non-COPD and COPD patients cultivated for five days. As baselineviability of the 3D-LTC varied between the patients, the measurement values needed to be normalized to themeasurement values of d0 for each patient respectively to make comparison possible. n=4-8. *: p<0.05, one wayANOVA with Bonferroni post-test.Taken together, murine and human3D-LTCwere analysed regarding morphological changes in 3D,specific cell types and their location inside the slice, cellular viability, as well as proliferativecapacity. Regarding the kinetic of the metabolic activity, no difference was seen comparing murineversus human 3D-LTC, healthy versus emphysematous, and non-COPD versus COPD, respectively.This gives evidence that 3D-LTC maintain viability over the cultivation of at least five days.
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5.3 Characterization of Wnt/beta-catenin signalling in 3D-LTCAs mentioned before, Wnt/beta-catenin signalling is reduced in COPD patients andemphysematous animals [Kneidinger, et.al., 2011, Wang, et.al., 2011, Zhou, et.al., 2012]. Therefore,we analysed whether these known alterations can also be detected in 3D-LTC, which is aprerequisite for using this technology for drug testing and mechanistical studies. The procedure ofagarose infiltration and fabrication of the 3D-LTC may have an influence on RNA expression of thecells. Wnt/beta-catenin downregulation may be affected by this. To control for such effects, RNAwas isolated and analysed from 3D-LTC directly after vibratome slicing. Wnt target genes, ligands,and receptors were significantly down regulated while Wnt antagonists were upregulated (Figure5.10). This gives evidence that Wnt signalling downregulation is present in 3D-LTC fromemphysematous mice.
Figure 5.10: Wnt signalling down regulation is retained in 3D-LTC from emphysematous mice.RNA expression of 3D-LTC from healthy and emphysematous mice was analysed directly after the generation of slices.n=7-10. *: p<0.05, **: p<0.01, ***: p<0.001, unpaired t-test with Welch’s correction.
5.4 Wnt/beta-catenin activation in 3D-LTC from emphysematous mice and
human patientsIt was shown before that Wnt/beta-catenin signalling was downregulated in 3D-LTC fromemphysematous tissue and in 3D-LTC from emphysematous mice. Wnt/beta-catenin activation isa possible target to induce repair. Therefore, Wnt/beta-catenin modulation is a target for drugdevelopment and testing to gain novel therapeutic options for COPD patients. The effect of pathwayactivation was further addressed in the present study. For reactivation of Wnt/beta-cateninsignalling two different GSK3 inhibitors were used as already mentioned before: LiCl and thechiron inhibitor CHIR99021 (CT), a compound more specific to GSK3 [Bain, et.al., 2007]. For most
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experiments, LiCl was applied to analyse the effect of Wnt/beta-catenin activation for lungregeneration, analysed by modulation of ATI and ATII cell markers. CT was used as proof ofconcept to show that the 3D-LTC model is reactive to other treatments for Wnt/beta-cateninactivation as well. With the 3D-LTC model, it is also possible to gain insight into the mechanismsof lung repair due to its 3D structure with allocation of all different cell types residing in the lungand thus benefiting of the perfect mimicking of the in vivo situation.
5.4.1 Toxicity of LiCl in 3D-LTCFirst, it was evaluated whether GSK3 inhibition with LiCl causes cell toxicity. For this, 3D-LTC weretreated with different amounts of LiCl in 0.1% FCS cultivation medium and WST-1 conversion wasanalysed. No significant toxicity was seen up to a concentration of 10mM LiCl while treatment with20 mM LiCl led to significantly reduced mitochondrial activity within 24 h showing that thisconcentration is toxic to the cells (Figure 5.11).
Figure 5.11: LiCl was not toxic to 3D-LTC from healthy mice up to a concentration of 10 mM.WST-1 conversion of the cells in 3D-LTC from healthy mice cultivated with varying concentrations of LiCl for theindicated time points. n=3. *: p<0.05, **: p<0.01, ***: p<0.001 compared to control treatment (0.1% FCS cultivationmedium), one way ANOVA with Bonferroni post-test.To verify, that 10 mM LiCl is not toxic in the 3D-LTC from emphysematous animals, which mightbe more susceptible to damage, the WST-1 test was repeated with those 3D-LTC as well. As shownin Figure 5.12, 10mM LiCl did not induce significant toxicity in 3D-LTC from emphysematous mice.For these reasons, a concentration of 10 mM LiCl was used for all following experiments to activateWnt/beta-catenin signalling.
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Figure 5.12: LiCl was not toxic to 3D-LTC from emphysematous mice up to a concentration of 10 mM.WST-1 conversion of the cells in 3D-LTC from emphysematous mice cultivated with varying concentrations of LiCl forthe indicated time points. n=3. one way ANOVA with Bonferroni post-test.
5.4.2 Effects of Wnt/beta-catenin activation by LiCl in murine 3D-LTCFirst, the activation of Wnt/beta-catenin by LiCl in the emphysematous 3D-LTC was evaluated byanalysing Wnt target gene expression. Axin2 as well as Dkk2 were significantly upregulated after6 and 24 h of treatment proving Wnt/beta-catenin activation on transcript level by LiCl (Figure5.13).
Figure 5.13: Wnt target gene expression was induced in 3D-LTC from emphysematous mice with 10 mM LiCl.Wnt target gene expression in 3D-LTC from emphysematous mice cultivated with 10 mM LiCl. n=4-10. *: p<0.05, **:p<0.01, ***: p<0.001, one sample t-test.Second, activation of the Wnt/beta-catenin pathway was determined by expression analysis of ABCprotein via Western Blotting. ABC protein expression was significantly increased after 24 h oftreatment with 10 mM LiCl in the slices from emphysematous mice giving evidence for thesuccessful activation of Wnt/beta-catenin via LiCl on the protein level as well (Figure 5.14).
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Figure 5.14: Active beta-catenin protein expression was significantly increased in 3D-LTC from
emphysematous mice with 10 mM LiCl.ABC protein expression in 3D-LTC from emphysematous mice treated with 10 mM LiCl for 24 h. left: representativeWestern Blot from 3D-LTC of two representative emphysematous mice, right: densitometry. n=5. *: p<0.05, paired t-test.The third method to verify Wnt/beta-catenin activation with LiCl was the treatment of 3D-LTCfrom emphysematous reporter animals (BAT-GAL and TCF/LEF-GFP [Ferrer-Vaquer, et.al., 2010,Maretto, et.al., 2003]). In 3D-LTC from both reporters LiCl led to an increase in the number ofpositively stained cells in the lung periphery (Figure 5.15).
Figure 5.15: LiCl led to an increase in Wnt/beta-catenin activated cells in the periphery 3D-LTC from
emphysematous mice.A: LacZ staining of 3D-LTC from emphysematous BAT-GAL Wnt-reporter animals treated with 10mM LiCl for 3 h. scalebar 20 µm, insert 100 µm. B: Confocal images of the GFP-staining of 3D-LTC from emphysematous TCF/LEF-GFPWnt-reporter animals treated with 10 mM LiCl for 72 h. Scale bar 50 µm.By the usage of live cell imaging of LiCl treated 3D-LTC from emphysematous TCF/LEF-GFP Wnt-reporter mice, the increase in Wnt-activated cells was confirmed by appearance of GFP-positivecells over time. Figure 5.16 shows an imaging time series from a video of the periphery with thosecells in the alveolar regions starting to express GFP over time.
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Figure 5.16: Live cell imaging reveals cells in the periphery of 3D-LTC from emphysematous TCF/LEF-GFP
Wnt-reporter animals becoming Wnt/beta-catenin activated over time.Live cell imaging picture series of a 3D-LTC from an emphysematous TCF/LEF-GFP Wnt-reporter animal. Images weretaken starting at 40 h of culture for 24 h with imaging every 30 min and are shown for a subset of time points. Circlesindicate cells, starting to express GFP due to Wnt/beta-catenin activation. Scale bar 100 µm.After proving successful activation of Wnt/beta-catenin signalling by the increased expression ofWnt target genes, the upregulation of ABC, and the increase in Wnt/beta-catenin activated cells, itwas important to identify which cells became activated. After LiCl treatment GFP-positive cells in3D-LTC from emphysematous mice stained positive for the ATII cell marker SFTPC and the ATI cellmarker podoplanin (Figure 5.17).
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Figure 5.17: Wnt/beta-catenin activated cells expressed markers for ATI as well as ATII cells.Immunofluorescent labelling of 3D-LTC from emphysematous TCF/LEF-GFP animals for podoplanin (PDPN) and pro-SFTPC after 72 h of treatment with 10 mM LiCl. A) PDPN and pro-SFPTC positive cells are indicated by white arrowheads and double positive (Wnt/beta-catenin activated) cells are indicated by yellow arrows. B) 3D reconstructionsof LiCl treated 3D-LTC from emphysematous TCF/LEF-GFP animals. Scale bar 50 µm.Further analysis of gene expression of specific markers was conducted to confirm Wnt/beta-catenin activation in ATI as well as ATII cells. LiCl induced no change in the expression of the ATIIcell marker Sftpc but led to partially differential expression of ATI markers. Pdpnwas significantlyupregulated after 6 and 24 h, Hopx was significantly downregulated at 24 h, while Aqp5 was notsignificantly changed (Figure 5.18).
Figure 5.18: Wnt/beta-catenin activation with LiCl did not alter gene expression of the ATII cell marker Sftpc
while ATI cell markers were differentially expressed in 3D-LTC from emphysematous mice.Gene expression of ATI and ATII markers in 3D-LTC from emphysematous mice cultivated with 10 mM LiCl. n=5-10.*: p<0.05, **: p<0.01, one sample t-test compared to hypothetical value 0.
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Subsequently, it was analysedwhether changes on mRNA level weremirrored on the protein level.For this, a SFPTC ELISA was applied showing no significant alteration in SFTPC expression afterLiCl treatment although there was a trend to lower expression (Figure 5.19).
Figure 5.19: Wnt/beta-catenin activation with LiCl did not significantly alter protein expression of SFTPC in
3D-LTC from emphysematous mice.SFTPC expression in cell lysates of 3D-LTC from emphysematous mice treated for 72 h with 10mM LiCl was measuredvia ELISA. n=7. paired t-test.Protein expression of the ATI markers was analysed via Western Blot. PDPN expression wassignificantly increased after 72 h of treatment with LiCl while AQP5 and HOPX expression was notsignificantly altered although HOPX tended to be expressed at lower levels after the treatmentwhich is in accordance to the gene expression data (Figure 5.20).
Figure 5.20: Wnt/beta-catenin activation with LiCl leads to differential protein expression of markers for ATI
cells 3D-LTC from emphysematous mice.Podoplanin and HOPX protein expression in 3D-LTC from emphysematous mice treated with 10 mM LiCl for 72 h. left:representative Western Blot, right: densitometry. n=5-6. *: p<0.05, paired t-test.In summary, the upregulation of Wnt target genes, the increase in ABC protein expression, and theincrease in the number of Wnt/beta-catenin-activated cells provide strong evidence, that GSK3inhibition, using LiCl led to activation of the Wnt/beta-catenin signalling pathway in 3D-LTC from
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emphysematous mice. The activated cells were ATI as well as ATII cells and can be tracked withlive cell imaging in a spatio-temporal manner.
5.4.3 Effects of Wnt/beta-catenin activation by LiCl in human 3D-LTCAfter having provenWnt/beta-catenin activation in ATI and II cells in 3D-LTC from empysematousmice, it was further investigated if LiCl can also activate Wnt/beta-catenin signalling in human 3D-LTC and whether there is a difference in the Wnt activation potential of non-COPD and COPDsamples. Due to limitation of the available samplematerial, it was not always possible to have bothgene and protein expression data from all patients. Furthermore, there was no significantdifference between the protein expression of 3D-LTC from non-COPD and COPD patients. Thismight be due to the small number of samples (for patient characteristics see Table 4.17). Hence,the results from non-COPD and COPD patients are shown as merged data and no discriminationwas conducted, except for the correlation analysis in Figure 5.26.After analysing Wnt/beta-catenin activation and its effect on epithelial cells in 3D-LTC fromemphysematous mice the same experiments were conducted in 3D-LTC from human patients. LiCltreatment led to significant increase of the Wnt target genes AXIN2 and NKD1 after 6 and 24 h,respectively, proving Wnt/beta-catenin activation on the transcript level of target genes (Figure5.21).
Figure 5.21: Wnt target gene expression is induced in 3D-LTC from human patients with 10 mM LiCl.Wnt target gene expression in 3D-LTC from human patients cultivated with 10 mM LiCl. n=4-10. *: p<0.05, **: p<0.01,***: p<0.001, one sample t-test compared to hypothetical value 0.Next, the activation status of beta-catenin after Wnt pathway modulation was analysed. ABC wassignificantly upregulated in 3D-LTC from human patients after LiCl treatment for 72 h as well,proving efficient Wnt/beta-catenin activation in these samples by LiCl (Figure 5.22).
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Figure 5.22: Active beta-catenin protein expression is significantly increased in 3D-LTC from human patients
with 10 mM LiCl.ABC protein expression in 3D-LTC from human patients treated with 10 mM LiCl for 24 h. left: representative WesternBlot, right: densitometry. n=5. *: p<0.05, paired t-test.Due to changes of Wnt/beta-catenin signalling in ATI and ATII cells as observed in 3D-LTC fromemphysematous animals, it was evaluated if these cell types are also activated in the human 3D-LTC. The effects of Wnt/beta-catenin activation on the transcript level markers for ATI and ATIIcells were analysed and are shown in Figure 5.23. Wnt/beta-catenin activation led to a significantincrease of the ATII cell marker SFTPC which was in contrast to the murine cultures, in which noalteration was seen. The ATI cell markers followed the same expression pattern already shown inthe murine cultures. PDPNwas significantly upregulated over time while AQP5 expression was notaltered. HOPX expression was significantly downregulated after 72 h which was seen alreadyearliest after 24 h in the murine samples.
Figure 5.23: Wnt/beta-catenin activation led to differential RNA expression of ATI and ATII cell markers in
3D-LTC from human patients.Gene expression of ATI and ATII markers in 3D-LTC from human patients cultivated with 10 mM LiCl. n=5-10. *:p<0.05, **: p<0.01, ***: p<0.001 one sample t-test compared to hypothetical value 0.Expression of ATI and ATII markers was confirmed on protein level. LiCl led to a significantupregulation of SFTPC protein expression as analysed by ELISA (Figure 5.24) which is inaccordance to its increase on transcript level.
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Figure 5.24: SFTPC protein expression was significantly increased by Wnt/beta-catenin activation with LiCl in
3D-LTC from human patients.SFTPC expression in cell lysate of 3D-LTC from human patients treated for 72 h with 10 mM LiCl was measured viaELISA. n=5. *: p<0.05, paired t-test.Similar as in 3D-LTC from emphysematous mice, PDPN protein levels were significantly increasedwhile HOPX expression was not significantly altered, but again, showed a trend fordownregulation. In contrast to the 3D-LTC from emphysematous mice, AQP5 was significantlydownregulatedwhich was contrary to its transcript level suggesting posttranscriptional regulationof AQP5 (Figure 5.25).
Figure 5.25: Wnt/beta-catenin activation with LiCl led to differential protein expression of markers for ATI
cells in 3D-LTC from human patients.Podoplanin and HOPX protein expression in 3D-LTC from human patients treated with 10 mM LiCl for 72 h. left:representative Western Blot, from 3D-LTC of two representative patients. right: densitometry. n=5-6. *: p<0.05, pairedt-test.Next, AXIN2 and SFTPC gene expression in the 3D-LTC was correlated with disease severity of therespective patients, revealing a significant negative correlation: Inducibility of AXIN2 and SFTPCgene expression was higher in patients with low FEV1/FVC value, as indicative for more severeCOPD (Figure 5.26).
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Figure 5.26: AXIN2 and SFTPC induction by LiCl in 3D-LTC from human patients correlates with disease
severity.RNA expression of AXIN2 and SFTPC after LiCl treatment for 24 h was correlated with FEV1/FVC value of individualpatients. n=12. Linear regression. The dashed lines indicate the 95% confidence interval.Taken together, Wnt/beta-catenin signalling by LiCl was efficiently activated in 3D-LTC from bothemphysematous mice and human patients as determined by increased target gene expression, ABCprotein expression, and increased number of Wnt/beta-catenin activated cells in 3D-LTC fromemphysematous Wnt reporter animals. LiCl treatment led to differential expression of ATI and ATIImarkers on transcript and protein level. Specific differences were observed in mice compared tohuman tissues for SFTPC expression, which was inducible in the human samples but not altered inthe murine ones, and AQP5, which was downregulated in the human samples but not altered in themurine ones. Correlation analysis demonstrates the potential of the 3D-LTC from human patientsas a predictive tool linking induction of gene expression with disease severity.
5.4.4 Wnt/beta-catenin activation by CT in 3D-LTCAs already mentioned before, Wnt/beta-catenin activation was additionally analysed with adifferent GSK3 activator, i.e. CT, as a proof of concept study to test novel drugs for therapeuticefficacy using 3D-LTC. First, the non-toxicity of the treatment with 2 µM CT was determined byWST-1 conversion of 3D-LTC from healthy mice. 10 mM LiCl and 20 mM LiCl were used asadditional control treatments. 20 mM LiCl, but not 10 mM LiCl, induced significant differences inWST-1 conversion by day three, proving once again, that 10 mM LiCl was not toxic. Neither 2 µMCT nor the respective DMSO control led to a reduction in WST-1 conversion giving evidence thatboth treatments (LiCl and CT) applied to the 3D-LTC used for Wnt/beta-catenin activation werenot toxic (Figure 5.27).
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Figure 5.27: 2 µM CT is not toxic to 3D-LTC from healthy mice.WST-1 conversion of the cells in 3D-LTC from healthy mice cultivated with 10 mM LiCl, 20 mM LiCl, 2 µM CT, andDMSO control. For better visualisation, the treatments were depicted in separate graphs. n=4. *: p<0.05, **: p<0.01,***: p<0.001 compared to control treatment (0.1% FCS cultivation medium), one way ANOVA with Bonferroni post-test.After excluding toxicity of the treatment, the small molecule CT was used in 3D-LTC from bothemphysematous mice and human patients for proof of concept experiments of Wnt/beta-cateninactivation. Axin2was significantly upregulated after CT treatment in the murine as well as humancultures after 6 and 24 h while Dkk2 and NKD1 were significantly upregulated after 24 h (Figure5.28, Figure 5.29). These results confirmed that Wnt/beta-catenin activation can be induced in 3D-LTC from emphysematous mice as well as human patients on transcript level by CT treatment.
Figure 5.28: Wnt target gene expression was induced in 3D-LTC from emphysematous mice with 2 µM CT.Wnt target gene expression in 3D-LTC from emphysematous mice cultivated with 2 µM CT. n=4-9. *: p<0.05, **: p<0.01,***: p<0.001, one sample t-test.
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Figure 5.29: Wnt target gene expression was induced in 3D-LTC from human patients with 2 µM CT.Wnt target gene expression in 3D-LTC from human patients cultivated with 2 µM CT. n=5-7. *: p<0.05, one sample t-test compared.As shown in Figure 5.30 and Figure 5.31 ABC protein levels were significantly upregulated in bothspecies after CT treatment for 24 h. Both the upregulation of Wnt target genes and increasedexpression of ABC provided evidence, that CT is able to induce Wnt/beta-catenin signalling in 3D-LTC similar to LiCl and can be applied as alternative drug in the model.
Figure 5.30: Active beta-catenin protein expression was significantly increased in the 3D-LTC from
emphysematous mice with 2 µM CT.ABC protein expression in 3D-LTC from emphysematous mice treated with 2 µM CT for 24 h. left: representativeWestern Blot from lung slices of two representative emphysematous mice. right: densitometry. n=5. *: p<0.05, pairedt-test.
Figure 5.31: Active beta-catenin protein expression was significantly increased in the 3D-LTC from human
patients with 2 µM CT.ABC protein expression in 3D-LTC from human patients treated with 2 µM CT for 24 h. left: representative WesternBlot from lung slices of two representative human patients. right: densitometry. n=5. *: p<0.05, paired t-test.
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5.5 TGF-beta activation in 3D-LTCTGF-beta is known to be involved in the development and progression of various diseasesincluding COPD and lung cancer [Massague, 2008]. TGF-beta has been shown to be oncogenic andinduce epithelial-to-mesenchymal transition (EMT) [Massague, 2008, Thiery, et.al., 2006]. For this,TGF-beta treatment was used as a further proof of concept study in order to evaluate the potentialof 3D-LTC that different signalling pathways can be modulated in 3D-LTC. As done before, 10 mMLiCl, 2 µM CT, and the DMSO-control were included into the WST-1 assay, to prove assayfunctionality and reliability (see Figure 5.27). TGF-beta did not induce cellular toxicity in 3D-LTC(Figure 5.32).
Figure 5.32: TGF-beta is not toxic to 3D-LTC from healthy mice.WST-1 conversion of the cells in 3D-LTC from healthy mice cultivated with 10 mM LiCl, 2 ng/ml TGF-beta, 2 µM CT,and DMSO-control. For better visualisation, the treatments are depicted in separate graphs. n=4. One way ANOVA withBonferroni post-test.Next, TGF-beta activation was analysed by detecting phosphorylated SMAD3 using Western Blotanalysis. Indeed, TGF-beta treatment induced SMAD3 phosphorylation in 3D-LTC from humanpatients as shown by an increase in the ratio of phosphorylated SMAD3 to total SMAD2/3 (Figure5.33).
Figure 5.33: TGF-beta treatment leads to induction of SMAD3 phosphorylation in 3D-LTC from human
patients.Phosporylated SMAD3 (pSMAD3) and total SMAD2/3 protein expression in 3D-LTC from human patients after 72 h oftreatment with 2 ng/ml TGF-beta. left: representative Western Blot, right: densitometry. n=6. *: p<0.05, paired t-test.In addition, several TGF-beta target genes were upregulated by TGF-beta treatment of human 3D-LTC such as PAI1 and smooth muscle actin (ACTA2), a (myo)-fibroblast marker, as well as the ECM
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protein COL1A1 after 24 and 72 h respectively, giving further evidence of TGF-beta pathwayactivation. In addition, the transcription factors SNAI1 and SNAI2, which have been implicated inEMT, were significantly increased in the human 3D-LTC (Figure 5.34).
Figure 5.34: TGF-beta treatments leads to increased expression of target genes, (myo)-fibroblast markers, and
transcription factor involved in EMT in 3D-LTC from human patients.Gene expression in 3D-LTC from human patients after different times of treatment with 2 ng/ml TGF-beta. n=4-10. *:p<0.05, **: p<0.01, paired t-test.Immunofluorescence staining of smooth muscle actin and collagen I of 3D-LTC from both healthymice and human patients showed increased staining in alveolar epithelial cell regions (Figure5.35).
Figure 5.35: Alveolar expression of smooth muscle actin (ACTA2) is induced by TGF beta treatment in 3D-LTC
from healthy mice and human patients.Immunofluorescence staining of smooth muscle actin (ACTA2) and collagen I in 3D-LTC from A) healthy animals andB) human patients after different times of treatment with 5 ng/ml TGF-beta. Arrow heads point to smooth muscle actinstained cells in alveolar regions due to TGF-beta treatment. Scale bars 100 µm.
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Taken together, the increase in target gene expression and factors involved in EMT demonstratesuccessful modulation of TGF-beta signalling and induction of disease relevant alterations in 3D-LTC from both healthy animals and human patients.
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6 DISCUSSIONCOPD is a progressive disease with no curative treatment options for aging patients (>50 y).Wnt/beta-catenin signalling is known to be downregulated in COPD and re-activation of thispathway has been shown to attenuate experimental emphysema in a mouse model of elastase-induced emphysema [Kneidinger, et.al., 2011, Wang, et.al., 2011]. The exact mechanism(s)underlying this disease are currently unknown. Furthermore, pharmacological interventionsshown to be effective in animal models still bear a high risk of failure in clinical trials [Malaney,et.al., 2014, Miller, et.al., 2011]. This makes the development of novel test systems and animalmodels for preclinical drug testing and pathway modulation studies important. In this work, theapplication of a 3D-LTC model for preclinical testing and analysis of molecular mechanisms wasestablished and validated.In the literature, precision cut lung slices (PCLS), are mainly used for pharmacological studies andonly short periods of time (24-72 h) [Liberati, et.al., 2010, Sanderson, 2011]. Up to now, a detailedcharacterization of this model has not been conducted. This is a significant difference to themethod of 3D-LTC presented in this work, in which cultivation was prolonged to seven days. Bysuccessful adaptation of the 3D-LTC to human samples, clinically more relevant results wereobtained. Reactivation of the signalling pathways Wnt/beta-catenin and TGF-beta provided proofof evidence for translational application and suitability of this model for preclinical drug testingand personalized medicine.
6.1 Characterisation of 3D-LTC
6.1.1 Influence of the process of slice generation3D-LTC from murine and human lung tissue had sustained ciliary beating and leucocytesmaintained motility in the tissue during cultivation. Cells remained viable, as assessed byLive/Dead assay and mitochondrial activity, significantly increased from day one to three, andremained stable thereafter. Proliferation peaked at day three and was enhanced by usage of ahigher amount of FCS (10%). Thereby, 3D-LTC remained viable for a cultivation period of at leastseven days (see 5.1). This is a significant improvement to the cultivation of lung slices reported byHenjakovic et al. who showed major cell death and nuclear degeneration in PCLS from rat tissueby 72 h [Henjakovic, et.al., 2008]. The main differences between their study and this work were:1) the method of slice fabrication (Krumdieck tissue slicer vs. vibratome), 2) the agaroseconcentration for the infiltration (1.5 vs. 2%), 3) slice thickness (200 vs. 300 µm), 4) immersionmedium utilized during slice generation (Earl’s balanced salt solution vs. cultivation mediumDMEM/F12 without FCS), 5) an additional washing step for 2 h in DMEM before cultivation doneby Henjakovic et al., and 6) the medium during experimental cultivation (no FCS vs. 0.1%/10%FCS). The thickness and concentration of agarose was more or less comparable between theprevious and current method —being 200 vs. 300 µm and 1.5 vs. 2%, respectively— therefore,
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differences in diffusion limitations can be excluded as a reason for the observed differences in theearly onset of cell death. One significant methodological difference is that while Henjakovic and co-workers used the rather harsh method of tissue slicing with the Krumdieck device, a more delicatemethod of cutting using a vibratome was applied for the generation of the 3D-LTC in this work.While slices were not washed before cultivation in this thesis, the additional washing step does notseem to influence cell viability, since the slices from Henjakovic contained hardly any dead cells atearly time points. They commented on addition of FCS in concentrations of 1%, 3%, and 10%,which led to increased cellular survival. Unfortunately, this data was not included into themanuscript, thus making it difficult to draw a conclusion regarding the length of this increasedcellular survival. Even though a rather low concentration of 0.1% FCS was used for 3D-LTC in thiswork, it possibly explains the difference in viability seen. Lastly, the method of slice generationused by Henjakovic may have induced cellular damage, which materialized at a later time point.Slicing with the Krumdieck device requires applying pressure on top of the tissue cores duringslicing. This may induce pressure-induced injury, which is lacking in the case of the vibratomewhere the tissue is glued onto a holder without compressing and further injuring the tissue.
6.1.2 Influence of the slice thickness and tissue densityThe most similar study in comparison to the current work is from Vaira and colleagues [Vaira, et.al.,2010]. Slices (300-500 µm) were generated from human cancer tissues (colon, prostate, and lung)using a vibratome as well, and cultivated with Ham’s F12 medium supplemented with 20% FCSand kanamycin. The MTT assay (a similar assay to WST-1 also utilizing a tetrazolium salt formeasuring mitochondrial activity) was used to determine cell viability. Although it did not reachstatistical significance, Vaira et al. observed a decrease in cell viability (~40-50%) on day three,five, and seven [Vaira, et.al., 2010]. These results are in contrast to the sustained and evenincreasing WST-1 conversion seen over the seven days of cultivation in the 3D-LTC described inthis thesis. A possible explanation for this is the tissue composition itself. As cancer tissue is moredense than healthy tissue, the thickness of the slices (300-500 µm) may have led to limitations innutrient supply and oxygenation, especially in the middle of the tissue. Cells inside the human bodyare not more then 100-200 µm apart from a capillary due to diffusion limits [Jain, et.al., 2005,Lovett, et.al., 2009, Rouwkema, et.al., 2008]. Furthermore, in tissue grown in vitro and re-implanted into the body, cells inside the re-implanted piece of tissue only survive within this samedistance range from capillaries [Jain, et.al., 2005, Lovett, et.al., 2009, Rouwkema, et.al., 2008]. Cellsfarther away die within a short time frame and lead to inflammation which may have been the casein the cancer slices described by Vaira and colleagues [Vaira, et.al., 2010]. Liver slices of the samethickness described by Vaira (500 µm) showed severe necrosis in the central area [Olinga, et.al.,1997]. Vaira and colleagues showed a non-significant but decreasing trend in proliferation withquantification of Ki67 staining being ~60% on day seven [Vaira, et.al., 2010]. Cells in the later timepoints staining positive for Ki67 were mostly restricted to the marginal areas of the slices andabsent in the middle. This is in agreement with the hypothesis, that cells in the middle are facing
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sub-optimal nutritional supply and oxygenation due to slice thickness and do not proliferateanymore. Interestingly, no significant increase in TUNEL staining was described suggesting thatcells did not become apoptotic/necrotic. In general the data is difficult to interpret as the resultsvaried between the different organs (colon, prostate, and lung) and patients, with some of themshowing opposite kinetics for both Ki67 staining and TUNEL assay [Vaira, et.al., 2010]. In starkcontrast, the 3D-LTC generated in this thesis do not exceed the passive diffusion limit since lungtissue has a lower tissue density per volume compared to cancer and cells never face a distance ofmore than a few micro meters to the next open airspace or alveoli where fresh, oxygenatedmedium is available. This suggests that limitations were not of concern in the 3D-LTC.A variety of methods have been utilized to assess slice viability. Umachandran et al. reported atime-dependant increase in LDH release (~ 50%) from rat lung slices within the first 24 h whichremained unchanged at later time points (48 and 72 h) [Umachandran, et.al., 2004]. Histologicalassessment using H&E staining of paraffin-embedded slices did not show correlative loss of tissuearchitecture or nuclear degeneration within the first 12 h but for incubations of 24 h and longer[Umachandran, et.al., 2004]. In this study the authors analysed the effects of slice thickness onmetabolic activity (exemplified by the metabolism of 7-ethoxycoumarin). Optimal thickness wasdetermined to be 600 µm (tested 420-700 µm) and thus thicker than the 3D-LTC used in this work.Slices were metabolic active for only 8 h compared to the prolonged mitochondrial activity untilday seven shown in this study. Usage of the Krumdieck tissue slicer additional to the higherthickness might explain this short period of metabolic activity.Next to metabolic activity, slice thickness is influencing cell viability. Due to the slicing of the tissue,cells at the margins are injured and die as indicated by Live/Dead staining (Figure 5.5 and Figure5.8). As dying cells secrete cytokines and cellular debris is left behind, this will possibly influencethe intact tissue function in 3D-LTC. The thicker the slice, the lower this influence will be.Optimisation of slice thickness in this regard was not conducted and not an aim of this thesis. Afuture study should determine the optimal thickness of the slices comparing the reduced negativeeffects of the dead cells at slice margins and their paracrine signalling (thick slices beneficial) withthe diffusion limitations for oxygen and nutrients (thin slices beneficial) [Liberati, et.al., 2010,Sanderson, 2011, Umachandran, et.al., 2004]. Nonetheless, it was assumed that cellular death atthe tissue margins did not have a major effect on the subsequent cultivation of the 3D-LTC in thisthesis, because the medium was changed before the pharmacological treatments started, therebyremoving dead cells, cellular debris, and cytokines secreted from dying cells.In summary, the generation of 3D-LTC by the method of vibratome sectioning led to viable culturesfor up to seven days, thereby showing improvement as compared to slice cultivation protocolsreported by other groups [Henjakovic, et.al., 2008, Umachandran, et.al., 2004, Vaira, et.al., 2010].Significantly increased proliferation was observed on day three by using 10% FCS cultivationmedium (see Figure 5.3), an effect, that was not reported up to now since most studies showed arather decreasing cell proliferation over time. The adaptations of the method for slice generationby using a vibratome in this thesis and the subsequent gentle handling of the delicate slices
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prolonged cell viability up to seven days. Nonetheless, cultivation of the 3D-LTC for longer periodsand analysis at late time points (day seven and later) might not lead to reliable results anymore.The drop in proliferation after day three may be due to the inability of the cells to maintain theiractivation status, which is supported by the decrease in intensity of the Live staining on day fiveand the stable and not further increasing WST-1 conversion. Cells might switch to a state, wherecellular function is just maintained but no tissue repair can be induced anymore. Sanderson stated:“In general, lung slice viability appears to be excellent for 1 to 3 days” [Sanderson, 2011]. Theresults from the viability and proliferation analysis in this work are in accordancewith this notion.All pathway modulation studies were conducted only up to three days to assure reliability ofcellular responses in the 3D-LTC. This issue should be addressed in further studies startingtreatments at a later time point after slice generation to gain knowledge if cells are still responsiveafter pre-cultivation of the 3D-LTC.
6.1.3 Influence of the cultivation medium and culture conditionsDifferent cultivation media and variations in FCS concentrations influence cellular behaviourregarding viability and proliferation (see 5.1). Moreover, medium composition alters cellularmetabolism, growth rate, and can favour the selective growth of certain cell types [Geys, et.al.,2007, Rehberg, et.al., 2014]. Liberati et al. reported on the different cell cultivation media used forslice cultivation [Liberati, et.al., 2010]. The medium used in this work (DMEM/F12) was describedpreviously to support cell viability [Liberati, et.al., 2010].It was stated by Liberati and colleagues that no FCS in the cultivation medium avoids “potentialconfounding influence of serum components on tissue reactions” [Liberati, et.al., 2010].Furthermore, Sanderson claimed that only sustaining cultivation media are needed and FCSsupplementation is not required to maintain slices viable [Sanderson, 2011]. This is in accordancewith the finding, that proliferation could be increased with higher amounts of FCS. A comparisonto media containing no FCS was not conducted in this thesis. The study from Delmotte et al., whoalso observed ciliary beating, revealed no differences when the experiments were conducted inserum-free cultivation medium or medium supplemented with 10% FCS [Delmotte, et.al., 2006].Accordingly, it was shown here that regarding mitochondrial activity the FCS content is notrelevant, while a higher FCS content in the cultivation medium is beneficial for the rate of cellproliferation (see 5.1). A detailed comparative study for optimising medium formulations tocultivate 3D-LTC has not yet been performed and will be critical in a future study. A standardizedmedium formulation for 3D-LTCmay be idealised as supporting viability and non-selective growthin all cell types. The aspect of oxygen concentration should be addressed in such a comparativestudy as well. This might overcome limitations of oxygenation in the middle of dense tissuecultures but needs to be carefully evaluated, since high oxygen concentration are potentiallyharmful.
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Taken together, the medium used for cultivation of the 3D-LTC and the FCS content of 0.1% wassuitable to keep cells viable. Cells in the middle of 3D-LTC were able to proliferate and react topathway specific treatments.
6.1.4 Influence of the cultivation techniqueIn this work, 3D-LTC were cultivated under submerged conditions in well plates. Nonetheless,there are other cultivation systems available as well. Some groups cultivate the slices on Transwellinserts to apply an air-liquid interface to them [Vaira, et.al., 2010]. One group compared fivedifferent incubation systems for rat liver slice cultivation over 24 h: a shaken flask (an Erlenmeyerin a shaking water bath), a stirred-well (24-well culture plate equipped with grids and magneticstirrers), a rocker platform (6-well culture plate with Netwell insert rocked on a platform), a rollersystem (dynamic organ culture rolled on an insert in a glass vial), and a 6-well shaker (6-wellculture plate in a shaking water bath) [Olinga, et.al., 1997]. While they observed no differenceduring short time cultivation, after 24 h the shaken flask, the rocker platform, and the 6-well shakerincubation systems were superior to the others regarding morphology, viability, LDH leakage,restoration of testosterone metabolism, Phase I metabolism, and restoration and maintenance ofenergy charge. Slices kept in the stirred-well cultivation system performed badly and were not ableto sustain cell viability up to 24 h. The authors suggested, that alternating exposure of the slices toair and medium are beneficial as was shown before [Smith, et.al., 1985]. Direct comparisons arelimited, since in this thesis no stirringwas applied to the 3D-LTC. Further, liver tissue is more densethan lung tissue and is more susceptible to nutrient and oxygen shortage. According to Sandersonhowever, the immersion of the slices in cultivation medium is sufficient to maintain cell viability[Sanderson, 2011]. For this reason, no stirring of the medium or perfusion of the 3D-LTC wasnecessary to maintain viability. In a study by Ghaedi and colleagues, ATII cells generated frominduced pluripotent stem cells (iPS) were cultivated in a rotating bioreactor system exposing thecells to air/liquid conditions. This cultivation was shown to be beneficial regarding ATII to ATItrans-differentiation making the application of small molecules to inhibit the Wnt/beta-cateninpathway unnecessary [Ghaedi, et.al., 2014].In conclusion, an optimized cultivation technique (e.g. perfusion cultivation or inclusion ofalternating air-liquid contact) may additionally enhance cell viability and long-term cultivation of3D-LTC. Future studies are needed to clarify the experimental parameters, which can be controlledto maximize the potential of 3D-LTC and are beneficial to induce specific cellular differentiation.
6.1.5 Benefits and limitations of the 3D-LTCThe benefits of the method of 3D-LTC established in this thesis are: the viability and capability ofthe cells to proliferate during cultivation (due to the freshness and quality of the starting material),the reduction of animal numbers and human sample material needed to conduct studies, the
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similarity to the in vivo environment, the broad range of applications, and the translation to othertissues/organs and diseases.
6.1.5.1 Biosample preparationThe “quality” of an organ influences its suitability for the 3D-LTC technique [Vickers, et.al., 2005].The shorter the time after explantation until experiments are conducted, the more reliable theresults will be. It is already known from organ transplantation that a short ischemia time isbeneficial [Souidi, et.al., 2013, Weyker, et.al., 2013]. In this work, the slices were generated fromfresh tissue. Mice were sacrificed and slices generated directly afterwards, being available fortreatments within one hour. The human 3D-LTC were similar. Due to the more complex procedureand the longer gelling-time, these were available for treatments after three to four hours afterexplantation. Therefore, it is supposed that the quality of the tissue was excellent and variationsbetween different batches of 3D-LTC were small. This was crucial for the prolongation of cellularviability and proliferative capacity over the cultivation period.
6.1.5.2 Reduction in sample materialWith the optimized protocol of 3D-LTC described here, cells stayed proliferative and were kept intheir natural environment, making a broad range of preclinical applications possible, such as livecell imaging, cell tracking, pathway modulation, and mechanistic studies. For gene expressionanalysis over time, a comparison of the different lobes (different regions) of the lung, from whichthe slices were generated, was conducted. Slices were pooled from different regions of one lobe (toobtain enough material for RNA isolation) and gene expression was compared to the other lobes.No inter-lobar differences were seen in 3D-LTC from healthy animals (data not shown). It wassuggested by Sanderson, that slices should be taken from different lung regions, in order to notbias the final findings [Sanderson, 2011]. This may not be necessary in non-treated, healthyanimals, where less regional differences are observed. The composition of the tissue, regarding theamount of alveoli was heterogeneous for both emphysematous animals and human samplesdepending on the region that was used for slicing. To not bias findings due to emphysemaheterogeneity, serial slices were used for the different treatments. By this, it was assured thatcontrol and treated slices originated from a similar region and differences observed were due tothe specific treatment. This is another benefit from the technique of 3D-LTC. Slices from onesample can be used for control and treatment, overcoming the issue of inter-individual variances.Furthermore, different methods, such as viability testing, morphological analysis, gene and proteinexpression, and live cell imaging can be conducted from one sample, thereby again reducing inter-individual variances and making results more robust and reliable. Consequently, the amount ofsamples necessary for a study is reduced as well. Less animals and patient material is required,decreasing the number of animals needed and making repetitive sampling unnecessary.
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6.1.5.3 Natural environment and cellular composition in 3DThere are distinct and striking advantages for using 3D-LTC. The three-dimensional structure ofthe tissue and the cells generally remain intact whereas cell isolation procedures and subsequentculture likely influences cellular behaviour. Physical contact and paracrine signalling with variousdifferent neighbour cell types is retained leaving the cells in a more physiological environmentsimilar to the in vivo situation. For that reason, it is possible to conduct cellular interaction studies,which is limited in normal in vitro single cell cultivation settings.Cellular composition, meaning the ratio of different cell types to each other, is the same as in vivo,which is almost impossible to recapitulate in vitro by co-cultivation systems. Every additional celltype adds complexity for interpretation. This is why co-culture systems are normally restricted totwo or three different cell types resembling the main components of the organ/site of tissuestudied. For the lung for example, an application called “lung on a chip” was established usinghuman alveolar epithelial cells and microvascular endothelial cells to reconstruct the alveolar-capillary barrier on an artificial, thin, porous, and flexible PDMS membrane [Huh, et.al., 2010]. Intheory more complex cell compositions can be used as well but one of the benefits of the 3D-LTCis the aforementioned natural environment, i.e. cellular matrix, the cells are facing. If cells areplaced in tissue culture wells or plates, the composition and mechanical properties of the matrixthey are confronted with are dramatically different from their in vivo microenvironment. Tissueculture plastic is very stiff (~3GPa), and even if coated with extra cellular matrix (ECM)components, it does not reflect the natural tissue stiffness (~1kPa for the alveolus) [Discher, et.al.,2005, Yang, et.al., 2014]. An alternative current approach to generate in vivo-like three-dimensional environments utilizes decellularising tissue with retaining ECM composition andrecellularising with one or more cell types. Cellular behavior and in particular the role of the ECMfor cellular function and cell fate decisions could be investigated by this [Bonvillain, et.al., 2012,Booth, et.al., 2012, Ghaedi, et.al., 2013, Gilpin, et.al., 2014, Sokocevic, et.al., 2013, Wagner, et.al.,2014].
6.1.5.4 Applications of 3D-LTC3D-LTC can furthermore be used for various applications such as high-resolution 4D live imaging.Internal organs are usually not easily accessible for imaging due to imaging artefacts produced bythe surrounding tissue. 3D-LTC are overcoming this problem, being directly accessible. Therefore,cellular behaviour and cellular pathways can be studied by ex vivo cultivation of 3D-LTC in real-time. This provides a permissible experimental setup to analyse all the components involved inendogenous tissue repair (discussed in 3.2.1.4) and was shown in this work (Figure 5.1, Figure 5.2,and Figure 5.16). Live cell imaging of 3D-LTC has not been used extensively in prior studies. Mostresearchers studying broncho-dilation/-constriction used standard transmission lightmicroscopy, owing to the fact that high resolution in the z-direction and labelling of specific celltypes is not necessary for determination of changes in bronchial diameter [Khan, et.al., 2007,Martin, et.al., 1996, Seehase, et.al., 2011, Sturton, et.al., 2008]. Live cell imaging using
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immunofluorescence staining was previously applied successfully to lung slices by de Proost et al.who imaged neuroepithelial bodies and their accompanying Clara cells after stimulation with50 mM potassium ions. Their experiments were only carried out until 12 h after animal sacrifice,since this was the longest time point without significant cell death [De Proost, et.al., 2008]. Imagingmainly focused on Ca2+-signalling, but did not include cell tracking. Ca2+-signalling is a fast processand is imaged within minutes, making long-term cultivation and prolonged cellular viability not amain prerequisite for the analysis. Another study successfully applied live cell imaging to studyciliary beat function [Delmotte, et.al., 2006]. In this study, cells were imaged for only short periods(on the scale of minutes) as well. The first published work on confocal imaging in lung slices wasconducted by Zhou and colleagues who induced local epithelial cell damage by a laser beam andimaged Ca2+-signalling and airway contractions [Zhou, et.al., 2012]. The extension of the live cellimaging to periods of up to 48 h described in this work is an improvement to the studies done sofar and gives evidence that cells can be tracked in 3D over time. With this, the method of 3D-LTC isapplicable to the whole range of genetically modified and lineage tracing/reporter animalsillustrating the remarkable value for the scientific community.Additional applications described in the literature include the use of vibratome slices from rat lungtissue to apply the patch clamp technique on single ATI cells to study their implication in ion andfluid balance over a period of 8 h [Bourke, et.al., 2005]. This study proves that the patch clamptechnique in combination with live cell imaging can be applied to 3D-LTC. Furthermore, distentionstudies combined with live cell imaging were conducted [Dassow, et.al., 2010, Davidovich, et.al.,2013] giving evidence, that 3D-LTC can be used to analyse ventilator induced injury and by thisproving its applicability to study various diseases. This further shows the broad range ofapplications the 3D-LTC can be used for.
6.1.5.5 Translation to other animal models, organs, and diseasesSimilarly, animals from other disease models can be used to generate 3D-LTC. To alternativelymodel COPD for instance, cigarette smoke can be applied to mice as main stream as well as sidestream smoke to simulate not only active but also passive smoking [John, et.al., 2014]. In contrastto the instillation of elastase, the cigarette smoke exposure animal model recapitulates both mainfeatures of COPD seen in humans, including airway remodelling as well [Antunes, et.al., 2011].Although it takes several months (approximately three to six months) of smoke exposure todevelop emphysema and the severity of the disease can only be compared to GOLD stage I and IIin humans [Churg, et.al., 2007] it would be of interest to include 3D-LTC from cigarette smokeexposed mice to validate the findings described in this work with another animal model.As mentioned before, the technique of 3D-LTC is already applied to various organs, such as brain,heart, liver, kidney, and lung [Liberati, et.al., 2010, Sanderson, 2011]. This is beneficial forpreclinical testing. A candidate drug, shown to be effective in a certain organ can be tested fortoxicity of its application route, without the need for testing it directly in the whole animal. Drugsare usually applied intra venous or ingested and thereby enter the blood circulation. The first
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organs affected are the liver and kidneys. 3D-LTC from both organs, tested in parallel to thecandidate drug, can give hints for the anticipated pharmacologic/toxic in vivo response. For thelung, this may be of minor importance since the accessibility of the injured areas via inhalation inpart overcomes drug delivery via the circulation.Furthermore, not only COPD and cancer can be studies by using the method of 3D ex vivo tissuecultivation. With slight adaptations, it can be applied to study any other lung disease, such asfibrosis, as well.
6.1.5.6 LimitationsA drawback of precision cut tissue slices may be the lack of the immune system and stem cellsupply after explantation and generation of the 3D-LTC. There is no connection to the blood systemanymore, therefore, no inflammatory or progenitor cells can migrate from the body into the slice.Effects studied with the model of 3D-LTC may therefore not exactly resemble the in vivo situation.Nevertheless, this may also be an advantage for studies where the effect of specific exogenousadded stem/progenitor or inflammatory cells is analysed.A further limitation is the lack of the air liquid interface inside the alveoli by usage of a submergedcultivation. Although some groups use tissue culture inserts to keep the slices at an air liquidinterface, a benefit from that is not proven up to now and needs further evaluation [Olinga, et.al.,1997, Vaira, et.al., 2010].The benefit of complexity of the tissue composition in 3D-LTC adds another drawback. Due to this,interpretation of results is difficult since different cell types may react opposite to a certaintreatment.The lung is constantly stretched and recoiled by the action of breathing. The natural occurringmechanical stimulation of the cells thereby is difficult to recapitulate within the 3D-LTC in vitro.One group developed a bioreactor to bi-axially stretch the slices [Dassow, et.al., 2010]. Stretchingthe 3D-LTC might be important for surfactant production, since ATII cells react to mechanicalstress with upregulation and increased expression of SFTPC [Dietl, et.al., 2010, Douville, et.al.,2011, Majumdar, et.al., 2012]. This is significant since SFTPC reduces surface tension and helps toprevent alveolar collapse and cellular damage [Lutz, et.al., 2015, Malacrida, et.al., 2014]. In vivo itwas shown that patients with COPD benefit from physical activity [Benton, 2014, Incorvaia, et.al.,2014]. The right amount of stretch is crucial because prolonged mechanical ventilation is knownto induce apoptosis of alveolar type II cells [Kroon, et.al., 2013]. Furthermore, oxygen supply needsto be carefully investigated and controlled. It was shown that hyperoxia (80-90% O2) increasedcell stiffness by actin cytoskeleton rearrangement and led to cell detachment during stretch[Wilhelm, et.al., 2014]. Taken together, stretch and the right amount of oxygen critically influencecell survival and differentiation, and thereby, the regeneration of the injured or diseased lungtissue and may be necessary components yet to determine.
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Even though, there are still limitations to overcome, the benefits of the method of 3D-LTC arepredominant over the disadvantages. The method is laborious but opens an avenue betweenanimal studies and clinical trials by the inclusion of patient material. As more companies providetissue slicers and vibratomes it is likely, that it will become a standard procedure in researchlaboratories in the near future.
6.2 Pathway modulation studies with 3D-LTCAs shown before, both signalling pathways studied in this work (Wnt/beta-catenin and TGF-beta)could be activated successfully without inducing significant cellular toxicity (see 5.4.1, 5.4.4, and5.5). For Wnt/beta-catenin activation two different GSK3 inhibitors (10 mM LiCl and 2 µM CT)were applied and showed similar strength in pathway activation. Both compounds have beenpreviously used in both in vivo and ex vivo models. LiCl was shown to attenuate experimentalemphysema by activating Wnt/beta-catenin signalling (predominantly in ATII cells) [Kneidinger,et.al., 2011]. Similarly, human fetal lung explants treated with 5 µM CT, showed an upregulation ofABC at the protein level {Zhang, 2012 #336}. These results are in accordance with the resultspresented in this thesis (5.4.4). Furthermore, the upregulation of different Wnt/beta-catenintarget genes (TCF4, LEF1,MMP7, CYCD1) were also observed [Zhang, et.al., 2012]. This shows thatboth compounds are capable of Wnt/beta-catenin activation.
6.2.1 Wnt/beta-catenin activationWnt/beta-catenin signalling has been reported to be reduced in emphysematous animals andCOPD patients [Kneidinger, et.al., 2011, Zhou, et.al., 2012]. Slice generation did not change thedysregulation of the Wnt/beta-catenin pathway and its downregulation was still detectable at theonset of cultivation of 3D-LTC from emphysematous animals (see Figure 5.10). From this it can beassumed, that differences seen ex vivo still reflect the in vivo situation and results from the ex vivomodel may be extrapolated in vivo.With the use of live cell imaging and BAT-GAL and TCF/LEF-GFP Wnt-reporter animals [Ferrer-Vaquer, et.al., 2010, Maretto, et.al., 2003] Wnt/beta-catenin activated cells could be identified andtraced (see Figure 5.16 and Figure 5.17). These studies could possibly be extended for studyingWnt/beta-catenin activation kinetics by quantification of the increase in activated cells over time.Activated cells were located in the periphery of the lung, staining positive for ATI and ATII markers(such as podoplanin and surfactant protein C). The identification of these cells, expressing markersof ATII cells was already shown before [Kneidinger, et.al., 2011], while the expression of ATImarkers was not described up to now.Slight differences in the expression pattern of ATI and ATII markers were seen comparing the 3D-LTC from murine and human tissue. In both, murine and human 3D-LTC, LiCl led to an increasedexpression of podoplanin and a decrease in Hopx. Aqp5 was significantly downregulated at theprotein level in the 3D-LTC from human patients, where in contrast, no regulation by LiCl wasdetected in 3D-LTC from emphysematous mice. While the ATII marker SFTPCwas not altered after
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LiCl treatment in 3D-LTC from emphysematous mice, its expression was significantly increased inhuman 3D-LTC stimulated with LiCl. This led to the speculation that ATII to ATI trans-differentiation was influenced by Wnt/beta-catenin pathway modulation.The exact role of Wnt/beta-catenin in ATII to ATI trans-differentiation is not yet known. It has beensuggested, that Wnt/beta-catenin activation during lung injury promotes differentiation to ATI-like cells [Flozak, et.al., 2010]. Flozak and colleagues showed that inhibition of beta-catenin/T-cellfactor signalling in primary rat ATII cells led to reduced expression of ATI markers (podoplaninand receptor for advanced glycation endproducts (RAGE)) and a decrease in cell survival. In directcontrast, Ghaedi and colleagues used a Wnt inhibitor (IWR-1) on ATII cells, generated from iPS.Wnt inhibition led to the induction of an ATI phenotype in these ATII cells [Ghaedi, et.al., 2013].Wang and colleagues observed that adenoviral overexpression of miR-375 in primary rat ATII cellsinhibited the Wnt/beta-catenin pathway and trans-differentiation to ATI cells [Wang, et.al., 2013].Marconett and colleagues used an integrated transcriptomic and epigenomic analysis of in vitrodifferentiated primary human alveolar epithelial cells to ATI cells and confirmed the activation ofthe Wnt pathway in this process [Marconett, et.al., 2013]. Taken together Wnt inhibition in primaryrat ATII led to trans-differentiation to ATI cells. The opposite results from Ghaedi may be explainedby the fact that the ATII cells were generated from iPS having an “ATII-like phenotype” [Ghaedi,et.al., 2013] and due to this could be different from primary ATII cells. Thereby it may be assumedthat Wnt activation will lead to increased ATII to ATI trans-differentiation in the 3D-LTC, whichthe increase in podoplanin and SFTPC in the human 3D-LTC was in accordance with.Thus far, it is believed that ATI cells arise from a pool of mature ATII cells which trans-differentiateinto ATI cells. This was seen for in vitro cultivation of isolated primary ATII cells several times bydifferent groups [Fehrenbach, 2001, Flozak, et.al., 2010, Ghaedi, et.al., 2013, Marconett, et.al.,2013]. However, recent evidence by Treutlein and colleagues suggests the existence of bipotentalveolar epithelial cells during murine lung development giving rise to ATI and ATII cells andexpressing markers of both lineages [Treutlein, et.al., 2014]. ATI cells might therefore stem fromtrans-differentiating ATII cells or this bipotent alveolar epithelial progenitor as a second source.Treutlein and colleagues showed that Hopx is a marker of ATI cells and was not detectable in fullydifferentiated ATII cells anymore [Treutlein, et.al., 2014]. A reduction of Hopx expression wouldbe indicative of either, a reduced amount of ATI cells or (assuming a non-changing amount of ATIcells) an increased differentiation of ATII progenitor cells (still expressing Hopx) to mature ATIIcells (lacking Hopx expression). Thereby an overall decrease in Hopx expression would bedetected.Podoplanin, another marker of ATI cells was showing increased expression in 3D-LTC from bothspecies but is not exclusively expressed by ATI cells, but for example endothelial cells [Herzog,et.al., 2013, Kunita, et.al., 2011] and fibroblasts [Inoue, et.al., 2014]. Even though slices werecarefully chosen to include mainly alveolar regions, small bronchi and vessels could not beexcluded to be located in the slices. Treatments affected all residing cells of the 3D-LTC, includingendothelial cells and fibroblasts, thereby complicating interpretation of the results, since thesecells may react with opposite regulation of podoplanin. The increase in podoplanin expression
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nonetheless is in accordance to the finding, that WNT3A treatment, a ligand activating Wnt/beta-catenin signalling, led to increased podoplanin expression in RLE-6TN cells (a cell line derivedfrom rat lung ATII cells) [Fujiwara, et.al., 2007]. By this, it was not unexpected that Wnt/beta-catenin activation may lead to an increase in podoplanin expression. The provider of the cellsquotes that these cells exhibit characteristics of ATII cells but did not comment on SFTPCexpression as marker for these cells. These cells might either be similar to the bipotent alveolarprogenitors stated by Treutlein et al. or already started to trans-differentiate into ATI cells, whichis known to happen fast during in vitro cultivation of ATII cells [Fehrenbach, 2001, Flozak, et.al.,2010, Ghaedi, et.al., 2013, Marconett, et.al., 2013].The ATI marker AQP5 is not exclusively expressed by ATI cells but bronchial acinar and ciliatedduct columnar cells as well [Borok, et.al., 2002]. The decrease in Hopx in 3D-LTC from bothemphysematous mice and human patients after LiCl treatment suggests a decrease in ATI cells.Aqp5 might decrease due to the fact that there are less ATI cells but its expression was not alteredin the murine 3D-LTC. This suggests that the bronchial acinar and ciliated duct columnar cellsmight have increased their AQP5 expression, leading to a non-altered overall expression. Theincrease in podoplanin might be explained by an increased expression in other cells, such asendothelial cells, compensating for the decrease due to less ATI cells. SFTPC expression was stablein 3D-LTC from emphysematous mice after LiCl treatment, suggesting that the ATII cell populationwas staying stable either by proliferation of ATII cells or differentiation of bipotent alveolarepithelial cells to mature ATII cells. Taken together this might indicate that in the murine slices theamount of ATI cells was decreasing while the ATII cell population stayed stable.In human 3D-LTC, an increased expression of the ATII marker SFTPC was detected due to LiCltreatment. This supposes a stabilisation or even increase of the ATII cell population. HOPX as wellas AQP5 expression were reduced, while podoplanin expression was increased leading to theassumption that the ATI cell population was decreasing in the human samples due to Wnt/beta-catenin activation, while the ATII cell population increased.The bipotent alveolar epithelial cells described by Treutlein et al.might still reside in the adult lungand may be located in the 3D-LTC as well, which has not been analysed thus far. If so, this pool ofcells could be a replenishing source for the trans-differentiating ATII cells and mature ATI cells.The study by Treutlein and colleagues was conductedwithmurine samples [Treutlein, et.al., 2014].For this reason, it is not known whether this bipotent progenitor population exists in human lungtissue as well, potentially leading to a different process of cellular turnover, in which only ATII toATI trans-differentiation in combination with proliferation of ATII cells is involved. For bettervisualisation, the concept proposed for the differentiation and cellular turnover in both species isdepicted in Figure 6.1. The exact mechanism of cellular differentiation was not addressed in thiswork. For this, cell tracking experiments, tracking the ATII cells and staining for ATI markersshould be conducted. Furthermore, it needs to be clarified whether a bipotential progenitor cellexists in the human lung, and if these cells reside in adult human tissue as well.
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Figure 6.1: Proposed differentiation of progenitor cells into ATI and ATII cells in the 3D-LTC after Wnt/beta-
catenin activation by 10 mM LiCl.Proposed differentiation in 3D-LTC from emphysematous mice (left) and human patients (right). The existence of abipotential progenitor cell in humans was not shown up to now.Wnt signalling is known to be essential for lung development and stem cell maintenance [Angers,et.al., 2009, Baarsma, et.al., 2013, Niehrs, 2012, Nusse, 2012]. Thus, future studies using thetechnique of 3D-LTC will be helpful to analyse whether Wnt pathway re-activation might lead tolung epithelial cell regeneration by specifically targeting the bipotent alveolar epithelialprogenitors (and thereby, leading to direct activation of the ATII and ATI cell population) orwhether Wnt signalling induces ATII to ATI trans-differentiation in human diseased lung tissue.
6.2.2 TGF-beta activationThe human lung specimen studied in this work originated from non-COPD and COPD patientsundergoing lung resection due to cancer. TGF-beta signalling is involved in COPD as well as cancerand shown to be lacking in emphysema, which is one of the main pathological features of COPD.Due to this, TGF-beta treatment was applied to the human samples to gain insight, if this pathwaycould be reactivated and potentially initiate lung repair.TGF-beta signaling is involved in chronic lung disease like fibrosis, COPD and cancer with differentlevels of activation. In fibrosis and the sites of peribronchial remodeling in COPD TGF-beta isupregulated [Beasley 2010, Churg 2006], while in the alveolar regions a lack of TGF-beta seems tobe causative for emphysema [Budd 2012, Milara 2013]. TGF-beta is also known to induceepithelial-to-mesenchymal transition (EMT) marked by loss of E-cadherin and an increase inexpression of alpha-SMA, collagen I, and the transcription factor genes SNAI1 and SNAI2 [Crosby2010, Grande 2002, Kim 2006, Milara 2013, Tanjore, H. 2011, Thiery 2006]. Induction of TGF-beta
78  DISCUSSION
signalling in human 3D-LTC by recombinant TGF-beta treatment resulted in induction of SMAD3protein phosphorylation and target gene upregulation (PAI1, COL1A1, and ACTA2) provingsuccessful pathway activation. Additionally, an increased expression of alpha-SMA protein inalveolar epithelial regions in both murine and human 3D-LTC was shown by IF. This stronglysuggests that distal epithelial cells may have undergone EMT in 3D-LTC, since the increasedexpression of alpha-SMA protein was seen primarily in alveolar epithelial regions. Moreover, thetranscription factors SNAI1 and SNAI2 were expressed at increased levels in human 3D-LTCtreated with recombinant TGF-beta.A number of in vitro studies have investigated the role of TGF-beta on specific lung cell types. Xiand colleagues treated A549 cells (human epithelial cells) with TGF-beta, and observed increasedSMAD2 and SMAD3 phosphorylation [Xi, et.al., 2014]. Furthermore, alpha-SMA, collagen I andSNAI1 protein expressionwere also found to be increased in the treated A549 cells [Xi, et.al., 2014].In a similar study, Câmara and colleagues found that TGF-beta-treated human bronchial epithelialcells (HBE) had increased expression of vimentin, alpha-SMA, phosphorylated SMAD2, and N-cadherin, while E-cadherin was decreased [Camara, et.al., 2010]. TGF-beta has also been shown toaffect alpha-SMA expression in lung fibroblasts. Treatment of primary human lung fibroblasts withTGF-beta induced up-regulation of alpha-SMA protein expression [Berschneider 2014, Kasabova2014].The increased expression of alpha-SMA that was observed in this work may be due to activation ofepithelial cells, undergoing EMT or alveolar-residing fibroblasts gaining a more myo-fibroblast-like phenotype. The exact cell type which stained positive for alpha-SMA in the alveolar regionswas not determined in this thesis. It would also be of interest whether TGF-beta treatment inducedATII to ATI differentiation in 3D-LTC, since it has been previously shown that TGF-beta treatmentpromoted trans-differentiation of murine primary ATII cells [Zhao, et.al., 2013]. Further analysisneeds to be done regarding which cell types are activated and whether this repair can occur indiseased tissue. Future studies utilizing slices from lineage tracing mice would also be helpful inelucidating which cell type most significantly obtains a myo-fibroblast phenotype.In summary, TGF-beta activation led to induction of EMT-related gene and protein expression in3D-LTC. As a lack of TGF-beta is related to emphysema [Budd, et.al., 2012, Milara, et.al., 2013] it isreasonable to assume that TGF-beta addition may lead to cellular reactivation and could possiblylead to lung repair.
6.3 3D-LTC as a tool for preclinical testingIn general, animal models are used to study human diseases. They are developed to mimic thedisease as close as possible. Nonetheless, animal models can only partially recapitulate humandiseases and usually lack the heterogeneity seen in patients. This may be one of the reasons whyonly 5% of anti-cancer drugs that succeeded in preclinical testing get approved by the Food andDrug Administration [Malaney, et.al., 2014]. “Mouse avatars”, a model in which pieces of the
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patients’ tumour are implanted into immunodeficient mice, is one approach for personalized drugtesting helping to find the suitable treatment for individual patients. Due to high costs andduration, this is not applicable to all patients why alternatives are needed. Directly studying thepatients’ tissue therefore is appealing. This can be achieved by the usage of 3D-LTC from humanpatients having the possibility for drug testing in a personalized medicine manner. Due to the highsimilarity of the human tissue and the 3D-LTC, the approach used in this thesis has the potentialto bridge the gap between animal studies and clinical trials.As previously discussed, murine and human samples expressed similar levels of podoplanin andHOPX but exhibited differences regarding SFTPC and AQP5 expression. While both markers werenot altered in murine 3D-LTC in response to LiCl treatment, gene and protein expression of SFTPCwas upregulated, while AQP5 was downregulated at the protein level in the human samples. Thereare a number of variables, which could explain the discrepancies observed between mouse andhuman samples. First, mice were young (age 8-12 weeks), while the samples from the humanswere from elderly patients (mean age 66±8 years). According to the findings from Zhou andcolleagues, there was no difference in emphysema development when they compared young andold mice exposed to cigarette smoke [Zhou, et.al., 2013]. This suggests that results from the animalexperiments might not have varied by using animals being in a comparable period of life matchedto the humans but needs further investigation to come to a definite conclusion.Second, the mouse model of elastase-induced emphysema is different from cigarette smokeinduced emphysema, one of the main features of COPD. Inflammation due to repeated cigarettesmoke-induced injury was absent in the elastase induced emphysema. In contrast to the mousemodels, human tissue came from patients, which all had cancer and a smoking history with amedian value of 51±18 pack years and lifetime exposure to environmental pollutants (see Table4.17). The missing inflammation, missing exposure to environmental pollutants, and missingcancer co-morbidity in the case of the emphysematous mice may have contributed to thedifferences seen between the 3D-LTC from both species.Although the mouse models are easy to handle, easily accessible, and a relatively cheap way tostudy diseases, human samples need to be studied in parallel to improve the probability thatresults that can be successfully transferred into clinical practice [Liberati, et.al., 2010, Vickers,et.al., 2005].The value of the 3D-LTC established in this work towards this aim is apparent. As alreadydiscussed, samples from a specific patient can be used in a personalized medicine manner. It ispossible to test the effects of a certain treatment for each specimen individually in a semi-highthroughput fashion. Furthermore, by using 3D-LTC from both mice and humans, we can furtherour understanding of the similarities and differences between the two species in lung disease. Mostprobably, this will help to predict, which findings are transferable and where dissimilarities wouldlead to non-transferable conclusions if experiments would be conducted in vitro or with animals,only.
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In this work, it was shown, that AXIN2 and SFTPC gene expression correlated with disease severity(see Figure 5.26) which was not shown in human 3D-LTC before. This gives evidence that 3D-LTCfrom human patients could be used as a predictive tool for drug testing in a personalized medicinemanner, tailoring treatments to the individual requirements of the patient. This might be onepotential avenue to anticipate adverse effects in patients and make drug testing safer beforeclinical studies are conducted. These results also suggest that even patients with more severeCOPD (e.g. GOLD stage IV, which were not included in this study) might benefit from theWnt/beta-catenin activation. A further study could contain a comparative evaluation of the treatment effectsin 3D-LTC and functional outcomes in the corresponding patient to further validate this model.This would help to predict the reaction of the patient to a certain pharmacological intervention ina fast and relatively easy accessible fashion.
6.4 ConclusionThis study characterised 3D-LTC from murine and human samples over a cultivation period ofseven days. Cellular viability, proliferation, and functionality was proven by various assays.Moreover, 3D-LTC were studied in a spatio-temporal manner using live cell imaging. This is animprovement compared to the studies performed until now, where long-term viability was amajorlimiting factor. In this work, it was demonstrated that different signalling pathways could beactivated in the 3D-LTC, shown specifically for Wnt/beta-catenin and TGF-beta. TGF-betaactivation resulted in an increased expression of transcription factors implicated in epithelial-to-mesenchymal transition in human 3D-LTC. Furthermore, a more unrestricted alpha-SMA proteinexpression in the alveolar epithelial cell region was observed suggesting that epithelial cellsexpress mesenchymal markers upon TGF-beta activation. Wnt/beta-catenin activation revealedactivation of ATI as well as ATII cells as shown by the use of Wnt reporter animals. Furthermore,markers for ATI and ATII cells were differentially regulated in response to Wnt/beta-cateninactivation indicating potential differentiation of ATII to ATI cells and thereby induction of repairmechanisms. This provides evidence that the Wnt signalling pathway is a potential target forpharmacological intervention in COPD management. The exact mechanism of activation was notdetermined in this study. Differences in response to treatments were observed between themurine and human 3D-LTC, highlighting the importance of studying human tissue for preclinicaltesting. Correlation analysis revealed a negative correlation of Wnt/beta-catenin activation withdisease severity on gene expression level, demonstrating that the 3D-LTC provide a valid tool toanalyse human tissue responses for preclinical drug testing and personalized medicine.In summary, it was shown, that different signalling pathways – the Wnt/beta-catenin as well as theTGF-beta pathway – can be activated in 3D-LTC. Wnt/beta-catenin activation was confirmed withtwo different pharmacological GSK3 inhibitors, and resulted in differential expression of ATI andATII markers in 3D-LTC from both emphysematous animals and human patients. Matrixalterations and cellular movements can be imaged with high spatio-temporal resolution in 3D
DISCUSSION  81
providing evidence for the suitability of the 3D-LTC for cell tracking and analysis of ECM repairmechanisms. Furthermore, inducibility of AXIN2 expression, as well as SFTPC, indicating ATII cellactivation after Wnt/beta-catenin activation with LiCl, can be correlated with disease severity ofthe patients. It is proposed that any signalling pathway can be activated in 3D-LTC. At least for thePI3K/AKT signalling pathway, successful modulation in tissue slices has already been shown[Vaira, et.al., 2010]. In this work, essential proof of concept for pathway modulation and drugvalidation in human 3D-LTC was provided, which we believe will open new avenues for superiorclinical translation and personalized medicine.
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